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Having a well-functioning immune system can mean the difference between a mild ail-
ment and a life-threatening infection; however, predicting how a disease will progress has
proven to be a significant challenge. The dynamics driving the immune system are governed
by a complex web of cell types, signaling proteins, and regulatory genes that have to strike
a balance between disease elimination and rampant inflammation. An insufficient immune
response will induce a prolonged disease state, but an excessive response will cause unnec-
essary cell dead and extensive tissue damage. This balance is usually self-regulated, but
medical intervention is often necessary to correct imbalances. Unfortunately, these thera-
pies are imperfect and accompanied by mild to debilitating side-effects caused by off-target
effects. By developing a detailed understanding of the immune response, the goal of this
dissertation is to predict how the immune system will respond to infection and determine
how new potential therapies could overcome these threats.
Computational modeling provides an opportunity to synthesize current immunological
observations and predict response outcomes to pathogenic infections. When coupled with
experimental data, these models can simulate signaling pathway dynamics that drive the im-
mune response, incorporate regulatory feedback mechanisms, and model inherent biological
noise. Taken together, computational modeling can explain emergent behavior that cannot
be determined from experiment alone. This dissertation will unitize two computational mod-
eling techniques: ordinary differential equations (ODEs) and agent-based modeling (ABMs).
Ultimately, they are combined in a novel way to model cellular immune responses across mul-
tiple length scales, creating a more accurate representation of the pathogenic response.
TLR4 and cGAS signaling are prominent in a number of diseases and dysregulations
including—but not limited to—autoimmunity, cancer, HIV, HSV, tuberculosis, and sepsis.
These two signaling pathways are so prevalent because they are activated extremely early
iv
and help drive the downstream immune signaling. Modeling how cells dynamically regulate
these pathways is critical for understanding how diseases circumvent feedback mechanisms
and how new therapies can restore immune function to combat disease progression. By us-
ing ODE and ABM techniques, these studies aim to incrementally expand our knowledge of
innate immune signaling and understand how feedback mechanisms control disease severity.
Figure 0.0.1: Visual Summary of Dissertation. Here, a visualization of the three aims in this
paper are illustrated. Every aim is built on understanding pathogen associated molecular patterns
either in the context of sepsis (Aim 1) or the cGAS pathway (Aim 2). Aim 3 extends the model
constructed in the second aim into a full multi-cell, agent-based model.
v
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1.0 Introduction
1.1 Innate Immune Signaling
1.1.1 Sepsis and Metabolism
When a cell detects a pathogen, a series of signaling events are triggered that lead to
the expression of genes that encode for potent immune signaling proteins. Some of these
proteins (i.e. cytokines) leave the infected cell to warn neighboring cells about the detected
threat, such as IFNβ [1], others will alter cellular function to prevent invading pathogens
from utilizing cellular machinery [2], and there are even proteins that are secreted by threat-
ened cells to induce apoptosis (programmed cell death) [3]. Unfortunately, this pathogen
detection mechanism is imperfect and can either be deceived (false negative response) or
inappropriately activated (false positive response). Cancer is prime example of a false nega-
tive response where the immune system should remove malignant cells but is subverted [4].
Cancer cells can accomplish this by expressing cell surface proteins that reduce immune cell
potency [5]. Conversely, sepsis is an example of a false positive response where the immune
system is activated unnecessarily. Figure 1.1.1 demonstrates how the immune system can be
activate far from the local source of infection.
Sepsis typically begins with a local infection isolated to one organ or area in the body.
Under normal circumstances, this pathogen can be removed by the immune system with ease.
However, if a pathogen or pathogen fragment enters the circulatory system, it can leave the
site of infection and relocate to a different organ (often the kidneys because they filter waste
from the blood). The pathogenic fragments are recognized by these distant cells and they
begin to trigger signaling pathways that upregulate more immune signaling proteins. This
process cascades until the entire body is in a state of rampant, uncontrolled inflammation
[6, 7].
One potential, and deceptively simple treatment to combat sepsis is to administer anti-
inflammatory medication to quell the exacerbated immune response. Unsurprisingly, nothing
1
Figure 1.1.1: Sepsis Overview. Sepsis is thought to be caused by the spread of pathogenic
signatures away from local infection. Here bacteria from the lungs are shown entering the blood
stream and being recognized by leukocytes. Without proper regulation, these processes can lead
to lethal, full-body inflammation.
is this simple in medicine. Pharmaceutical intervention aimed to suppress the immune
system runs the risk of allowing the original infection to worsen. The treatment would
have to be given after the infection is cleared, but before the patient succumbs to organ
failure. Paradoxically, even when controlling for this scenario, sepsis clinical trials using
anti-inflammatory drugs notoriously fail. Dr. Bone wrote a commentary on this issue over 20
years ago [8] and still today current CDC guidelines to treat sepsis are limited to antibiotics,
maintaining blood flow to organs, and treating the source of the infection [9]. Despite
these efforts, 30% of the 1.7 million sepsis cases in the United States each year end in
death [10]. To improve our chances of developing successful sepsis treatments, we need to
look beyond simply reducing inflammation and investigate how else this condition impacts
cellular function.
In recent years, there has been increasing evidence that metabolism plays a crucial role
during sepsis [11, 12, 13]. Metabolism, generally, is the collection of chemical reactions
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that occur throughout the cell to maintain cellular function. Different metabolic pathways
are classified as either anabolic, meaning they use energy to synthesize new molecules, or
catabolic where they break down molecules to produce energy. The metabolic pathways
affected by sepsis are catabolic and are, namely, the oxidative phosphorylation (OXPHOS)
and aerobic glycolysis pathways. OXPHOS is considered the default metabolic pathway that
occurs in the mitochondria to produce ATP and relies on a continuous supply of oxygen to
fuel the electron transport chain, a multi-step redox process the generates an electrochemical
gradient to drive the synthesis of ATP. Glycolysis, on the other hand, occurs in the cytosol
and is composed of a series of chemical reactions that transforms glucose into pyruvate,
generating ATP in the process. This process can occur without oxygen, but will eventually
convert pyruvate into lactate, a metabolic dead-end that cannot be further decomposed to
produce energy. Typically, cells will use OXPHOS to produce ATP and switch to glycolysis
when oxygen is depleted (hypoxia), however, during sepsis, cells are observed to switch to
glycolysis despite normoxic conditions (hence aerobic glycolysis) [11, 14, 15]. This is often
referred to as the famous Warburg effect which is utilized by cancer cell to meet their high
energy requirements [16].
Understanding which metabolic pathway is active during sepsis is important because it
determines how a cell’s immune system will respond. Cells shifted toward aerobic glycolysis
will enter a resistive state, meaning a pathogenic threat is actively being responded to by the
immune response, increasing inflammation (see Figure 1.1.2). Cells that remain in OXPHOS
exhibit what is known as a tolerant state where cells reduce inflammation to avoid injury
caused by an excessive immune response.
Given this idea of resistive and tolerant states associated with metabolism, one would hy-
pothesize that shifting cells away from aerobic glycolysis and toward OXPHOS could improve
the outcome of sepsis. However, there is still much to learn about this mechanism as re-
cent studies have suggest that cells undergo biphasic or even cyclic shifts between metabolic
states [17, 13]. A single shift toward OXPHOS might not be sufficient. To understand
metabolic shifting, computational modeling approaches are used to simulate pathways con-
trolling metabolism. If models can reconstruct this mechanism, they could be used to test
different septic states to determine how this shifting results from known signaling pathways.
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Figure 1.1.2: Balancing Metabolic States. Cells have evolved to leverage one of two immunologic
states: Resistive or Tolerant. A resistive state occurs when a cell is actively preventing the ad-
vancement of a pathogen. Cells in this state utilize glycolytic metabolism. A tolerant state allows
a cell to ignore an infection to reduce the risk of injury caused by the immune system. Cells in this
state utilize OXPHOS metabolism.
1.1.2 cGAS Pathway: Sensing DNA
The story behind cGAS begins with a mystery about how cells detect viral invaders.
A virus is more or less a package of genetic material surrounded by a capsid, or shell of
proteins that protect this genetic material and facilitate its transport. The genetic material
can vary in structure depending on the type of virus. Influenza A, for example, is comprised
of eight single-stranded RNA molecules that encode for capsid proteins as well as immune
suppressing proteins to ensure the success viral proliferation [18]. Herpes Simplex Virus
(HSV-1), in contrast, is encoded by a one double stranded DNA molecule that encodes for
the entire virus. Still other viruses like human immunodeficiency viruses (HIV) have more
complex life cycles because it is encoded by RNA which is then reversed transcribed into
DNA when HIV enters a host. The immune system needed to evolve ways to identify this
foreign genetic material and differentiate it from its own DNA and RNA molecules. If a cell
4
could make this distinction, an immune response could be triggered to combat the virus and
return to a healthy state.
The method in which cells detect foreign RNA has been established and well understood.
It has been shown that RNA is detected through RIG-I like receptors (RLRs, [19]) and toll-
like receptors (TLRs, [20]) which promote the activation of transcription factors (e.g. IRF3
and IRF7) and production of type I interferon (IFNα and IFNβ) [21]. Interferon was given
this named because it was observed to “interfere” with viral infections. Interferon acts as
a master regulator for hundreds of interferon stimulated genes (ISGs) that prevent viruses
from proliferating at every step of the infection process [2].
In contrast, the mechanism underlying the recognition of double stranded DNA (dsDNA)
in the cytosol remained elusive. Beginning in 2006, there was evidence for dsDNA inducing an
IFNβ response, but no definitive signaling pathway was known to explain this observation
[22]. Over the next seven years, there were no fewer than seven potential DNA sensors
identified but none were met with universal acceptance [23]. This mystery remained unsolved
until 2013 when Sun et. al. provided the first definitive evidence that cyclic GMP-AMP
synthase (cGAS) was indeed the putative molecular sensor of cytosolic dsDNA [24].
They further demonstrated that cGAS binding of dsDNA catalyzes the formation of
cyclic guanosine monophosphate adenosine monophosphate (cGAMP), a secondary messen-
ger molecule the binds to a protein bound to the ER called stimulator of interferon genes
(STING). As it names suggests, STING undergoes a conformational change after binding
to cGAMP, translocates to the perinuclear space to phosphorylate the transcription factor
IRF3 [25], which then upregulates interferon transcription (for a more detailed diagram of
this signaling pathway, see Figure 3.1.1). This connects cGAS to the more-established RIG-I
and TLR pathways, finally creating a clear molecular mechanism linking dsDNA detection
to the interferon response.
While the cGAS pathway was identified in the context of viral infections, it also plays
pivotal roles in wide range of biological contexts. Many types of cancers, for example,
have mutated to specifically downregulate cGAS expression because it bolsters an immune
response to prevent tumor growth [26, 27]. Surprisingly, there are instances where the cGAS
pathway promotes inflammation-mediated tumor growth [28, 29]. The interplay between
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cancer and cGAS is more complex than previously thought and would greatly benefit from
modeling techniques derived from systems biology.
Of course, when dysregulation occurs in an immune response pathway, autoimmune
diseases are likely to surface. The cGAS pathway is no exception to this and has been
implicated in lupus erythematosus [30] as well as rarer diseases such as Aicardi-Goutieres
syndrome (AGS) where a primary deoxyribonuclease, TREX1, is functionally inactive [31].
TREX1 is responsible for degrading DNA signals that activate cGAS, which if left untreated,
can lead to chronic inflammation.
Figure 1.1.3: Roles of cGAS in Disease
Finally, cGAS has been discovered to be a critical component in cellular senescence [32], a
process where cells have reached the limit to which they can undergo mitosis. This limitation
is to ensure that the accumulation of mutations within the genome is controlled. Usually,
after about 50 divisions, signaling events occur to cause the cell to apoptose. cGAS has been
shown to detect damaged DNA the accumulates in the cytosol due to errors in cell division
[32, 33]. Senescence also have a significant impact on stem cell development as these cells
are rapidly dividing and differentiating [34].
Because the success of cGAS signaling is linked to an incredible number of biological
processes, it is imperative that this potent immune response be tightly regulated. There are
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a few key downstream regulators that control the cGAS pathway and subsequent interferon
response, one being the previously mentioned TREX1 protein. cGAS activates TREX1
which then degrades DNA to subdue cGAS activity. Another class of proteins that inhibit
the downstream effects of cGAS are Suppressor of cytokine signaling (SOCS) proteins. These
class of proteins are upregulated by an interferon response and works to stop incoming
interferon signals by inhibiting its surface receptor [35].
cGAS signaling can also be enhanced by positive feedback mechanisms. The transcription
factor IRF3 is activated by cGAS to promote the expression of IFNβ. As interferon protein
concentrates, another transcription factor (IRF7) is expressed to overtake the role of IRF3
[36]. Because IRF7 is induced by IFNβ which produces more IRF7, strong inflammatory
signals can be amplified in this positive feedback loop if left unchecked.
This leads to a need to quantify how the cGAS pathways is regulated and predict how
the immune system changes when the pathway is manipulated (either artificially through
pharmaceutical intervention or gene knock down). The immune system is a nonlinear dy-
namic system, which implies that changes in inputs (e.g. the amount of DNA) do not scale
with changes in outputs. Reducing the activity of cGAS by 50% will not coincide with an
equal reduction in IFNβ expression. In fact, some cells within a population will exhibit no
interferon expression despite receiving immunostimulatory DNA (ISD) [37]. To predict how
the immune response is going to evolve over time, we need to turn to computational model
approaches. In conjunction with experimental observations, these modeling paradigms can
help propel our understanding of cGAS pathway regulation and help identify new system
behaviors that could not be determined though experiment alone.
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1.2 Computational Modeling
1.2.1 Using Ordinary Differential Equations in Systems Biology
There are two main approaches in biological research that are used to understand exper-
imental observation. The first, more traditional method, takes a reductionist approach by
breaking down complex biological phenomena into its basic components until the underlining
cause is found. Gene knockout studies are an excellent example of this approach. By iso-
lating a primary function of a gene or mechanism within a cell, critical knowledge is gained
which can be used to refine a signaling pathway that was previously unresolved or propose
a new pharmaceutical target. An insurmountable number of discoveries have been found
using this approach and it is usually regarded as the gold-standard for biological research.
However, this approach is not infallible due to the complex, non-linear relationships that
drive biological mechanisms.
Systems biology takes the opposite approach by considering multiple biological compo-
nents simultaneously. This more recent, holistic approach benefits from information derived
from traditional experiments, and can further identify behavior that only emerges when mul-
tiple components come together. Kitano outlines this idea effectively in his seminal paper,
Systems Biology: A Brief Overview :
“Because a system is not just an assembly of genes and proteins, its properties cannot be
fully understood merely by drawing diagrams of their interconnections. Although such a
diagram represents an important first step, it is analogous to a static roadmap, whereas
what we really seek to know are the traffic patterns, why such traffic patterns emerge, and
how we can control them.” [38].
This illustrates an important distinction between the structural and dynamic aspects of
biology. Knowing a protein is inhibited by another is important, but it provides minimal
information about how that protein interacts with other biological components within the
entire cellular system.
A classic example of successfully utilizing systems biology is demonstrated in Hoffmann’s
work investigating the regulation of NF-κB. This protein is associated with a myriad of
biological processes including the innate and adaptive immune response, apoptosis, survival,
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and cell growth [39]. NF-κB is perpetually inhibited by IκB proteins through direct binding,
which prevents it from acting as a transcription factor to promote gene expression. When
specific signals are detected by a cell (e.g. viral RNA), an enzyme phosphorylates IκB,
releasing NF-κB, and allowing it to translocate to the nucleus. Interestingly, IκB genes
are one of the many genes regulated by NF-κB, meaning its activation eventually leads to
auto-inhibition. This probably would have been the endpoint to understanding of NF-κB
signaling if the entire system was not further considered. Undeterred, Hoffman continued
his examination of the pathway and discovered NF-κB levels can oscillate depending on the
dynamics of the input stimulus. This had major implications for which genes NF-κB could
activate. Some genes like IP-10 would be expressed after a short impulse (15 minutes) of
stimulus, but others like RANTES needed significantly longer stimulus exposures (2 hours)
to observe detectable levels of protein. This temporal regulation effectively allows the cell to
select which NF-κB genes are expressed despite all being regulated by the same transcription
factor.
How were these NF-κB oscillations predicted? There are no traditional biological meth-
ods that would have predicted this observation which is why system biology approaches were
implemented, specifically in this case ordinary differential equations (ODEs). This branch
of mathematics focuses on how a system changes over time and are ubiquitous in science.
They can be used to describe simple Newtonian motion like a swinging pendulum or more
complicated phenomena like particle wave functions from quantum mechanics. In the case
of NF-κB regulation, the following system of ODEs was used:
NF-κB IκB
S
Figure 1.2.1: Two Component NF-κB
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d[NF-κB]
dt
= S − α[NF-κB]− β[IκB] (1.1)
d[IκB]
dt
= γ[NF-κB]− δ[IκB]. (1.2)
These equations relate the change in protein concentration over time to the current
protein concentrations in the cell. Here, both proteins have a rate of self degradation (α
and δ) which captures the idea of proteolysis. The rate of IκB production is increased by
NF-κB (through the γ term), allowing subsequent NF-κB production to be inhibited by the
increasing IκB concentration (through the β term). This linear system of ODEs can exhibit
a variety of behaviors depending on the values of the rate constants, and because the system
is linear, we can easily determine what parameter values correspond with particular system
outcomes. By vectorizing the system of equations:
d
dt
NF-κB
IκB
 =
S
0
+
−α −β
γ −δ
NF-κB
IκB
 , (1.3)
it can be shown that the eigenvalues of the rate constant parameter matrix determine the
system behavior.
p(λ) = det(A− λI) (1.4)
p(λ) = det
−α −β
γ −δ
−
λ 0
0 λ
 (1.5)
p(λ) = λ2 − (α + δ)λ+ (αδ − βγ) (1.6)
p(λ) = λ2 + TrA λ+ detA, (1.7)
Here, Tr and det are the trace and determinant of the rate constant parameter matrix.
Plotting the trace of the rate constant parameter matrix against the determinant, we can
easily summarize all the possible behaviors of this system (Figure 1.2.2).
Because the trace of the NF-κB parameter matrix is always negative, and the determinant
is always positive, the system will remain stable (staying within the blue region of Figure
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Figure 1.2.2: Characteristic Dynamics of a Coupled Linear System of ODEs. The blue region
indicates stable solutions converging toward equilibrium. TrA and detA denote the trace and deter-
minant of the rate constant parameter matrix. ∆ represents the discriminant of the characteristic
polynomial (Eq 1.4). The different subplots show possible system behaviors where the two axes
represent the two components evolving over time.
1.2.2). If the degradation rates for NF-κB and IκB (α and δ) were large and the interaction
terms were large (γ and β), the system would smoothly converge to an equilibrium point
(sink region). Conversely, if the degradation rates were large and the interaction terms small,
the system would experience damped oscillations (spiral sink). This is precisely what was
observed experimentally for dynamic NF-κB measurements [40].
Small, linear ODE systems are straightforward to analyze because we can rely on tech-
niques developed in linear algebra. However, these systems become intractable to analyze
after the introduction of more components (proteins) and non-linear terms (x2, xy, 1/(a+x)).
This is the case if we want to model large signaling pathways using mass-action and Michaelis-
Menten style kinetics (often used to describe enzymes). When a system describing a cell
signaling pathway contains these non-linear terms we can either create a linear approxima-
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tion (usually though Taylor series expansions) or—if the system is small enough—use phase
portraits as shown in Figure 1.2.2. Although, anything beyond three states becomes too dif-
ficult to visualize using this method. One way to overcome these shortcomings is to simulate
the system of ordinary differential equation (ODE) numerically.
There is a rich history behind solving ODEs numerically (see [41, 42]), but the algorithms
can be largely classified into either explicit or implicit methods. Explicit methods can use
the current time point to directly calculate the next, whereas implicit methods require a
set of equations to be solved to resolve the next time point. This can be accomplished
by estimating the derivative as a finite difference. While implicit methods tend to require
additional computations, they also exhibit greater numerical stability. To demonstrate the
advantages each class of algorithm brings, we will explore two of the simplest algorithms
from each class.
Starting with the explicit Forward Euler Method, if we have a differential equation:
dy
dt
= f(t, y(t)), (1.8)
where f(t) is some well-behaved (i.e. continuous) function, then we can make an approxi-
mation of the derivative by its definition:
y(t+ ∆t)− y(t)
∆t
≈ f(t, y(t)). (1.9)
We can now solve for the future value of our unknown function (y(t+ ∆t)) given the current
value at time t
y(t+ ∆t) = y(t) + f(t, y(t)) ·∆t. (1.10)
This works well if ∆t is taken to be a small value. When the approximation in Eq. 1.9 was
formed, a choice for indexing was made. It is just as correct to say:
y(t)− y(t−∆t)
∆t
≈ f(t, y(t)), (1.11)
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which can be simplified to the familiar backward Euler algorithm.
y(t) = y(t−∆t) + f(t, y(t)) ·∆t. (1.12)
But there is something wrong with Eq. 1.12, the new value for y(t) cannot be isolated
directed because it happens to be an argument for the function f . To get the next value
for y(t) the system would have to be solved for algebraically or estimated using fixed-point
iteration.
A plethora of more advanced ODE algorithm exist. Some utilize the Jacobian to gain
higher order derivative information about the system, others have adaptive methods that
change ∆t depending of the current error estimation. Despite these complexities, almost
every ODE solver works by estimating the derivative with a finite difference and taking
sufficiently small steps in time to solve the system. By employing these algorithms in a
systems biology context, we can simulate how the concentrations of proteins and molecules
change over time. This is an invaluable tool because it provides a way to predict everything
from how cells will respond to changes in their environment down to how genes are activated
over time.
1.2.2 Markov Chain Monte Carlo
Developing ODE models of cellular signaling pathways inevitably leads to a substantial
number of unknown parameters that need to be determined. Conventionally, parameteriza-
tion is performed by measuring all states within the system at a sufficiently dense number
of points in time and fitting these measurements to simulation. This optimization would be
accomplished by minimizing the sum-of-square differences between the measurements and
model simulation, resulting in a best-fit value for each parameter. In addition to being in-
tractable from an experimental perspective, this method is flawed because it ignores two
problems in parameter optimization: local minima and identifiability. Local minima are
regions within the parameter space that appear to give the best-fit value if you limit your
search to a small neighborhood of surrounding points, whereas identifiability occurs when
there is many parameterizations all equally minimize the objective function.
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Figure 1.2.3: Example Objective function. Red dots indicate local minima and the orange line
demonstrated a region of parameter space that is not identifiable.
Figure 1.2.3 gives a pedagogical demonstration of how tuning one parameter value might
lead to either of these problems. Depending on the initialization of the parameter, common
optimization methods (i.e. gradient decent algorithms) will either report a value of ±7 (red
dots indicating local minima) or within the range [−3, 3] (orange line representing an iden-
tifiability issue). If the optimization was performed only once close to a local minimum, it
would lead to an inaccurate conclusion about the best-fit parameter value. Alternatively,
choosing an initialization anywhere within the non-identifiable region would lead to ambi-
guity into exactly what is the best-fit value. All the parameter values between -3 and 3 give
the same sum-of-squared error between the measurements and simulation.
Overcoming either scenario requires sufficient topological knowledge of the parameter
space, which can be challenging especially in higher dimensional spaces. To combat these
problems, we turn to a Bayesian inference approach. Instead of determining what parameter
value best fits the data, we instead ask: what is the probability a parameter takes on a
particular value, given the experimental evidence? Posing the question in this way allows
us to think of the parameters not as a single value, but as a collection of continuous values
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each with an associated probability. This paradigm is dependent on Bayes Formula:
P (θ|D) = P (D|θ) · P (θ)
P (D)
. (1.13)
Here, we are trying to determine the posterior P (θ|D), the probability that a particular
parameter set θ explains the given data D. The right side of the equation consists of the
likelihood P (D|θ) which tells us how good the data fits to a given parameter set, the prior
P (θ) which summarizes any information we might know about the parameters beforehand,
and the evidence P (D) which indicates if the data was generated by the model. The posterior
probability cannot be calculated directly, so instead it is numerically estimated by sampling
many parameter values using a method called Markov Chain Monte Carlo (MCMC).
The basic MCMC algorithm begins with some initial parameter set. To determine how
good this parameter set is, we calculate the likelihood that our data came from this parameter
set. If we assume the error in our data is Gaussian (with zero mean and unknown variance
σ2), the likelihood function reduces to the familiar sum-of-square error
P (D|θ) ∝ exp
(∑n
i=1(y˜ − yi)2
2σ2
)
, (1.14)
where y˜ is our simulated model being subtracted from each to the n total data points (yi).
With this information in mind, MCMC proposes to “jump” to a new location in parameter
space and calculates the likelihood of the candidate parameter set. The algorithm now
needs to decide if the candidate parameter set will be accepted, which is accomplished by
calculating an acceptance ratio between [0, 1] and comparing it to a uniform random number
within that same range. The acceptance ratio is calculated by evaluating the ratios of the
posterior distributions:
α = min
(
1,
P (θi+1|D)
P (θi|D)
)
= min
(
1,
P (D|θi+1) · P (θi+1)
P (D|θi) · P (θi)
)
, (1.15)
where θi+1 represents the candidate parameter set, and θi the current parameter set. The
acceptance ratio cleverly uses Bayes formula (Eq. 1.13) to calculate the posterior distribu-
tions using just the likelihood and prior distributions, both of which are known. The prior is
conventionally given a uniform distribution if no information is known a priori. Note that if
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the posterior of the candidate parameter set is greater than the current posterior (α = 1), it
will automatically be accepted when compared to a uniform random number. However, even
if the candidate parameter set increases the total error, it could still be accepted with some
probability. This ultimately allows the Markov chain to visit all of parameter space, but
remain in areas longer if they have a high probability of containing the “best” parameter
set, effectively eliminating the problem of local minima. In Figure 1.2.4 we can see how
counting the number of times the Markov chain visits a parameter value gives us a distri-
bution we can use to parameterize the model. Areas of high probability are visited more
often by the Markov chain which leads to a larger peak on the histogram. Additionally, this
algorithm sidesteps some identifiability issues because we can move our focus to investigating
different model behaviors the top parameter sets exhibit as opposed to fixating on the best
parameterization.
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Figure 1.2.4: Demonstration of MCMC Parameterization
Many MCMC methods are available to perform parameter optimization, but based on
a recent review by Ballnus et al. [43], we chose to use the toolbox PESTO to implement a
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parallel tempering (PT)-MCMC algorithm in conjunction with multi-start local optimiza-
tion. Briefly, PESTO begins by using an interior-point minimization routine in MATLAB
(fmincon) initialized from 1,000 randomly distributed starting points. These starting points
are determined using Latin Hypercube Sampling. (PT)-MCMC then uses these local min-
ima and gradient information to initialize the algorithm. As it executes, multiple chains
are run in parallel, each having an associated temperature that dictates how easily a new
candidate parameter set is accepted (Figure 1.2.5). Increasing the temperature has the effect
of flattening the posterior probably density. Chains are also allowed to swap locations which
allows lower temperature chains to further investigate minima found by higher temperature
chains.
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Figure 1.2.5: Combining Parallel Tempering with MCMC. The density plot represents a posterior
probability distribution with areas of low (blue) and high (yellow) probability density. MCMC
chains are depicted as jumping through parameter space, with higher temperature chains exploring
disparate parameterizations more rapidly. Chains will randomly swap positions where, occasionally,
lower temperature chains are placed in higher probability regions as demonstrated in the swap
shown.
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These amendments to the original Metropolis–Hastings algorithm are not necessary—in
theory—because MH-MCMC is guaranteed converge to the target distribution. However, the
rate of convergence in many circumstances is often intractable, so the addition of multi-start
local optimization and parallel tempering routines are used to accelerate this process.
Determining when an MCMC simulation has converged is a difficult task and is still
an active area of research. The best tools currently available for this are diagnostics and
rules-of-thumb. Generally, we can only determine if a simulation has failed. Because the
posterior distribution is unknown, we can never be certain if the entire distribution was
sampled. One of the first and easiest ways to determine a successful MCMC simulation is
to look at the parameter chain (i.e. the history of the parameter values). If these appear to
randomly cover the parameter space, it would be evidence toward a healthy simulation, but
if the values appear to depend on one another, this could indicate that the proposal jump
is too small. This can be quantified by calculating the auto-correlation between the MCMC
samples.
Another test for MCMC simulations is to examine the acceptance rate. If the algo-
rithm is rejecting nearly every proposed jump, the time to convergence will substantially
increase. Theoretical estimates put the ideal acceptance ratio at approximately 23% [44],
but in practice, the assumptions that go into this estimate are often broken. Nevertheless,
this acceptance ratio is often used as a rule-of-thumb.
The last, more computationally intensive diagnostic for MCMC is the Gelman-Rubin
diagnostic [45]. This test requires that multiple simulations are run to compare how signif-
icantly different posterior estimates are within chains compared to between chains, If one
chain happened to explore a unique area in parameter space, it would mean that the MCMC
simulations have not yet to converged to the posterior distribution.
By performing all of these diagnostics and checking different rules-of-thumb, we can
convince ourselves that the MCMC simulation(s) accurately capture the full posterior dis-
tribution.
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1.2.3 Multi-Scale Agent-based Modeling
There are many approaches used to model how a cell dynamically evolves over time.
ODEs, as described in Section 1.2.1, are useful for modeling intracellular dynamics because
they provide a means to easily convert a chemical signaling pathway into a mathematical
framework that predicts cell responses to stimuli (e.g. bacteria, cytokines, hypoxia). There
are other methods beyond ODEs that, generally, exchange benefits and limitations to better
answer specific research question. One example are Petri-Nets where each component in
a signaling network is given a discrete number of tokens representing the concentration of
that species [46]. Dynamics are simulated by moving tokens around the network. A node
can transfer tokens across a connection if it has the required number of tokens matching or
exceeding the connections toll (edge weight). This discretization can be useful in modeling
small molecular concentrations typical to cells. Another commonly used method in system
biology is Boolean modeling [47]. Here, each protein or gene in a network is only considered
to be in an “on” or “off” state and logical operators are used to connect this binary states (e.g.
if transcription factor 1 and transcription factor 2 are on, then gene A is also on). These
types of simulations are useful if the signaling networks are large and amount of kinetic
data is sparse. All of these methods can, to some degree, be used to model extracellular
interactions within a cell population, but invariably make strong assumptions about the
spatial layout of a cellular population. ODE modeling, for example, is required to assume
no changes in spatial distributions over time. SIR (susceptible, infectious, recovered) models
are a good example of this assumption in action. Typical cell-based SIR models [48] simulate
cell population dynamics as an infectious agent causes healthy cells to transition infected and
recovered states. The distribution of virus across the population is assumed to be equal and
any cell within the population can be infected regardless of their neighboring cells’ status. To
incorporate important spatial information into these modeling schemes, a different approach
needs to be utilized.
Agent-Based Modeling (ABM) is one such solution to this dilemma. ABM itself is an
umbrella term that covers a wide range of different algorithms and modeling techniques, but
all share some common attributes. First, agents (usually in our case cells) are generated and
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given a set of intrinsic properties ranging from geometric (like volume or area) to domain
specific (like cell type or initial velocity). Second, rules are put into place that instruct the
agents how to behave in the simulation. For example, an agent with one attribute might be
attracted to an agent with that same attribute. Rules might change the number of agents
in a simulation, update specific cell attributes, or even occur randomly. The depth and
complexity of these rules is only limited by imagination and computing power. Third, a
simulation space for the agents to live in is defined. This could be as simple as a discrete
grid of points or contain no grid in continuous 3D space. Agents could be defined as points
or span a large region in the space defined. Agents could even be defined in other agents
(this would be useful for modeling a mitochondrion inside a cell). Forth, and last, a schedule
needs to be created that determines how the rules are enforced as each step in time. This
is important because rule order impacts the result of the simulation. If I define two rules:
(1) remove a random agent and (2) add two new agents, depending on the execution order,
I could end up with a steady population of agents or infinitely many agents.
In addition to providing a foundation for modeling spatial variations in a cell population,
ABMs are also useful for simulating the heterogeneous and stochastic properties impacting
cellular signaling. Heterogeneity here refers to differences in molecular concentrations across
each cell in the population. This can impact cell signaling potency because some cells could
have an insufficient amount of protein to recognize the immunologic threats. Stochasticity,
with regard to cell signaling, can be broken down into intrinsic and extrinsic sources. In-
trinsic sources originate from the cell itself like low concentration levels, whereas extrinsic
sources are extracellular events causing different cellular responses. ABMs can incorporate
these observed behaviors in contrast to models like reaction-diffusion PDEs which do incor-
porate spatiotemporal variations but are deterministic in nature. Figure 1.2.6 categorizes the
potential for ODE, PDE, and ABM modeling paradigms based on desired attributes. Ideally,
models would be able to simulate large cellular populations that incorporate spatiotemporal,
heterogeneous, and stochastic behaviors.
In recent years, modelers have found success in hybridizing ABMs with ordinary and
partial differential equations [49, 50, 51]. The procedure to accomplish this is difficult because
the available software to model advance ABMs (e.g. Netlogo [52]) is typically not integrated
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Figure 1.2.6: Comparing Model Strengths and Weaknesses
with advance ODE solver suites (e.g. SUNDIALS [53]). One method formulated in this
dissertation to combine ABMs and ODEs works by adapting the DifferentialEquations.jl
Julia package [54]. This package provides advanced, adaptive, ODE solvers that can handle
large scale systems by leveraging algorithms like automatic sparsity detection, Jacobian
coloring, and choices for linear solvers.
When the ODE solver successfully progresses to the next time point, a series of callback
events are initiated. Callback events are typically used to simulate discontinuities that arise
in a physical system, one example being an ODE system modeling the position and velocity
of a bouncing ball. When the ball makes contact with the ground, the velocity abruptly
changes sign allowing the ball to bounce away from the ground. This can be modeled with a
callback event that checks if the position of the ball matches the ground. Generally, callback
events change either the value of the ODE state or parameter. We can adapt these callbacks
to implement ABM rules into the ODE system. For example, one callback event that was
assigned to the model in Aim 3 was used to transition a cell from an infected to a dead state.
After a fixed amount of time after infection, all parameters associated with transcription and
translation are set to zero. This ad hoc application of callback events is surprisingly flexible,
and can be used for more complex ABM rules like adding or moving agents.
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A hybridized ODE/ABM model substantially improves the capability of modeling a cell
population responding to a pathogenic threat, but still fails to capture intercellular com-
munication. Cellular communication is liaised though the diffusion of cytokines, specialized
proteins that bind to neighboring cell surface receptors to initiate signaling pathways. Dif-
fusion can be modeled using partial differential equations (PDEs) through Fick’s Law:
∂f
∂t
= D∇2f, (1.16)
where f is species concentration (a function of space and time), D is the diffusion coefficient,
and ∇2 is the Laplacian operator. To incorporate this term into the ODE/ABM model, the
PDE can be discretized into system of ordinary differential equations and augmented onto the
cell signaling dynamics. The time derivative is left unchanged, but the spatial derivatives are
approximated by a finite differences. This technique, often referred to as “Method of Lines”
provides the major advantage of only needing one ODE solver, as opposed to separate solvers
for simulating diffusion and intracellular signaling. The main disadvantage is the resulting
size of the system to solve. If a 2-dimensional plane is discretized into 100 segments on each
dimension, the accompanying ODE system will have a total 10,000 equations in addition
to systems of ODEs controlling cell signaling. Careful consideration needs to be taken to
successfully solve this large system without encountering computer time or memory issues.
The Laplacian is discretized using a central order difference method:
∇2f(xi, t) =
n∑
i=1
∂2f(xi, t)
∂x2i
≈
n∑
i=1
f(xi + ∆xi, t)− 2f(xi, t) + f(xi −∆xi, t)
∆x2i
, (1.17)
where ∆x is the finite difference approximation and n is the number of spatial dimensions.
A central difference method is used as opposed to a forward or backward method because
the accuracy of the approximation is proportional to the square of the grid spacing (∆x2i ).
Combining these modeling schemes (see Figure 1.2.7) coalesce into a hybrid model ca-
pable of simulating cellular immune responses across multiple spatial scales. The ODEs are
used to model changes in intracellular protein concentration over time, PDEs track protein
diffusion across a cell population, and ABMs allow cells to probabilistically react to changes
to their environment and infectious pathogens encoded by rules.
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ODE Model
Intracellular signaling
PDE Model
Cytokine Diffusion
Cell Model
Growth and Division
d[cGAS]
dt
= −k1f ⋅ cGAS ⋅ DNA + k1r ⋅ cGASc
Figure 1.2.7: Hybridizing ODE PDE and ABM Models. Each component of the hybrid model
provides a different methodology to simulate a cell population. ODE models are used to track
intracellular concentrations over time. PDE modeling allows protein signals to diffuse across the
cell population. Cell/ABM Modeling incorporate rules (like the spread of a virus) that influence
the current state of the ODE/PDE model.
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2.0 Predicting Metabolic Reprogramming in Septic Induced Acute Kidney
Injury
2.1 Introduction
Sepsis is a serious medical condition where an aberrant activation of the immune response
causes severe, widespread inflammation throughout the body. This activation is initiated by
pathogen associated molecular patterns (PAMPs) that enter the circulatory system and
disseminate from the origin of infection to induce proinflammatory cytokine production in
distal organs despite any sign of local infection. If left untreated, sepsis can quickly devolve
into organ dysfunction and, in 30% of the 1.7 million cases in the United States each year,
death [10]. The kidney is one of the earliest and most frequently afflicted organs during
sepsis, as acute kidney injury (AKI) presents in up to 60% of patients in septic shock [55].
Clinical trials for potential anti-inflammatory therapeutics demonstrate poor efficacy because
we lack a mechanistic understanding of the dynamics governing sepsis [56]. To rectify this
critical knowledge gap, we turn to computational modeling to identify how sepsis-induced
changes in cellular function within the kidney promote AKI.
Sepsis can be experimentally emulated by stimulating renal tubular epithelial cells (TEC)
with lipopolysaccharide (LPS) [57], a typical PAMP found within the cell membrane of
gram-negative bacteria [58]. TECs detect LPS by binding toll-like receptor 4 (TLR4) pro-
tein [59], resulting in a signaling cascade that triggers interferon production [60], releases
proinflammatory cytokines, and regulates the infiltration of antigen presenting cells (APCs)
and macrophages [61]. Inflammation provides a method to directly resist an infection with
the goal of reducing pathogenic loads, despite substantial collateral tissue injury sustained
or metabolic resources required.
While several computational studies of LPS-induced signaling have identified mechanisms
key to regulating intracellular immunity, most studies do not consider a critically important
feature associated with inflammation: metabolic reprogramming [62, 63]. In a process known
as tolerance [11], cells change the metabolic pathways used to produce energy, and, in doing
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so, prioritize healing associated functions over functions directly targeted at resolving the
pathogen. For example, a cell may reprogram itself to use a less efficient metabolic route
(aerobic glycolysis) to minimize the production of oxidative byproducts causing cellular
damage and tissue injury [64]. The cell can tolerate the infection to deal with the more
immediate threat of cell death due to the ongoing immune response. It is also hypothesized
that this metabolic reprogramming provides the cell with an opportunity to mount more
effective inflammatory responses by allocating energy toward the production of more essential
substrates, increasing overall cell survival [65, 66]. Switching from high energetic to lower
energetic metabolism to produce metabolites for cell proliferation has been famously observed
in tumors, referred to as the Warburg effect [14, 67]. The processes of resisting and tolerating
infection work in tandem to maximize pathogenic clearance and minimize injury resulting
from the host immune response.
Because metabolism plays a crucial role in regulating immune responses in sepsis [11,
68], it needs to be incorporated into computational models to accurately depict disease
progression and outcome. The importance of metabolism suggests that both resistive and
tolerant responses to inflammation play a significant role in governing the dynamics driving
sepsis. Previous models of the immune response to sepsis focus only the direct inflammatory
resistance and do not incorporate the impact of tolerance through metabolic reprogramming
[69, 70]. It has been established that exposure to sepsis inducing bacteria signatures like LPS
circulating in the blood reach TECs and downregulate ion transporters including ATP pumps
which changes how cells produce energy [71]. This metabolism reprogramming induced by
sepsis causes TECs to switch between normal efficient oxidative phosphorylation (OXPHOS)
to the abnormal inefficient aerobic glycolysis via the Akt/mTOR pathway [11, 72].
Modeling metabolism switching in the context of sepsis has not been investigated, but the
signaling pathways governing the metabolism have been modeled extensively (see [73, 74, 75]
for the PI3K/Akt/mTOR pathway, [76, 77] for glycolysis, and [78] OXPHOS). By compiling,
modifying, and contextualizing these models to LPS induced sepsis, we aim develop an ordi-
nary differential equation model to determine what metabolites or cytokines are responsible
for controlling metabolism switching, and show how the dynamics of this biphasic response
lead to better cell survival.
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2.2 Material and Methods
2.2.1 Establishing Signaling Pathways for Metabolic Reprogramming in Sepsis
Metabolic reprogramming, which has been demonstrated TECs during sepsis, occurs
when cellular metabolism shifts from normal oxidative phosphorylation (OXPHOS) to aero-
bic glycolysis—despite ample oxygen availability. This process is referred to as the Warburg
Effect and is controlled by several intersecting signaling pathways that include key regula-
tors such as AMPK, mTOR, Akt, and HIF-1. The first step in building a computational
model was to construct a comprehensive map of these regulators to determine the network
structure connection these signaling pathways (see Figure 2.2.1).
Both OXPHOS and glycolysis function to convert AMP to ATP, allowing the cell store
energy and utilize it maintain cellular mechanisms (e.g. gene expression, molecular transport,
etc.). One key regulatory protein that for ATP production is AMPK, which functions as
a physiological cellular energy sensor due to its sensitivity to fluctuating AMP levels [79].
When intracellular ATP is reduced to AMP, it binds to the γ subunit of the heterodimer,
promoting activation. The phosphorylation of AMPK on Thr172 in the activation loop can
also respond to the calcium flux via the CAMKII kinase, so it was included as an additional
regulator of AMPK activity [80, 81]. AMPK is an enzyme that plays a vital role in cellular
energy homeostasis and thus, in the metabolic shift, acts as a critical control point for both
the oxidative phosphorylation and glycolysis pathways.
With evidence that AMPK phosphorylates TSC2 under energy starvation conditions
[81], the connection to the mTOR pathway is established through the inverse relationship
between the TSC2 and Rheb protein; it was found that TSC2 inhibits Rheb-induced mTOR
signaling by reverting Rheb to its inactive GDP-bound state [82]. Rheb, a small GTPase,
has been shown to bind to mTORC1 complex and cause a global conformational change that
activates the complex allosterically [83, 84]. Experimental observations show that mTORC1
directly increases the stability of HIF-1α [82], a protein that is constitutively expressed, but
quickly targeted for ubiquitination [85]. Upon stabilization of HIF-1α, it binds with the
HIF-1β to generate the heterodimer HIF-1 complex.
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Figure 2.2.1: Sepsis Pathway Diagram. The pathways controlling two major metabolic routes
(OXPHOS and glycolysis) are illustrated above. Both catabolic pathways work to enhance ATP
production, which is controlled by AMPK and HIF-1 activity. ATP and AMP directly bind to
AMPK (shown as light and dark blue circles near AMPK), which acts as a controller to maintain
their ratio. AMPK phosphorylates TSC2 which inhibits Rheb activation and binding to mTORC1.
This inhibition is reversed by Akt which is activated by LPS stimulation. With LPS stimulus,
mTORC1 is activated to stabilizes HIF-1α and enhance aerobic glycolysis. SIRT6 opposes this sta-
bilization when AMPK phosphorylation is pronounced. ROS, a byproduct of OXPHOS, increases
HIF-1 complex formation and enhances CaMKII activity to drive further AMPK phosphorylation.
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HIF-1 increases the metabolism of glucose using two mechanisms. First, glucose trans-
porters (GLUT1) are upregulated to increase glucose flux into the cell [86]. And second,
HIF-1 upregulates glycolytic enzymes like lactate dehydrogenase A (LDH-A) to facilitate
the metabolism of glucose into downstream products like pyruvate and lactate. [87].
2.2.2 Integrating Immune Activation into the Metabolic Shift
In this model, LPS is used as a proxy to simulate cellular response to sepsis. LPS,
an endotoxin from gram-negative bacteria, is recognized by Toll-like receptor 4 (TLR4) to
initiate the innate immune signaling cascade [88]. The activated cell surface receptor can
then stimulate the PI3K/Akt pathway, causing tyrosine phosphorylation of surface receptors
of PI3K and subsequent molecule phosphorylation of the Akt kinase catalytic region [89].
Akt can completely inhibit TSC2, and as a result, affect the metabolic state of the cell
[90, 91]. Furthermore, SIRT6, a NAD+-dependent deacetylase, is activated by AMPK and
represses HIF1a transcriptional activity [92]. In addition to affecting metabolism through the
Akt/PI3K pathway, LPS has also been shown to inhibit AMPK activation and potentially
play a significant role in the downstream metabolic shift from OXPHOS to glycolysis [93].
2.2.3 Developing the ODE System
The combination of this experimental evidence led to the development of the model
structure depicted in Figure 2.2.1 with the corresponding ODE model summarized in Ap-
pendix B.1. The model consists of 23 states representing protein species in the pathway and
31 parameters that dictate the dynamics driving the evolution of these states. All states
are modelled using mass action kinetics except for the conversion between AMP and ATP.
The OXPHOS and glycolytic pathways were each lumped into one term which would make
this kinetic model inappropriate. Instead, the ATP production rate was modelled to be pro-
portional to AMPKp and HIF-1 activity to represent OXPHOS and glycolysis, respectively.
The basal consumption rate of ATP was set to be constant. These rates were informed by
experimental studies conducted by Mookerjee et. al. where they quantified intracellular
glycolytic and oxidative ATP flux [94]. The steady state concentrations for ATP and AMP
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are larger in magnitude than other signaling proteins and were taken to be 9600 µM and
280 µM respectively [95].
Proteins that could be present in two different states (e.g. AMPK and AMPKp) were
constrained via mass balance, which assume no additional translation or degradation of these
proteins. Some species like HIF-1α did have production and degradation rates. Many of these
rates were unknown, so they were set to average protein translation and degradation rates
based on measurements from hundreds of proteins [96]. The degradation rate of HIF-1α was
known and set to value of 5 min−1 [85].
To simulate the model, the DifferentialEquations.jl package in Julia was used in conjunc-
tion with the DiffEqBiological.jl package [54]. This method uses a Domain Specific Language
(DSL) for writing chemical reactions which we use to define the pathways controlling OX-
PHOS and glycolysis metabolism. A system of differential equations is automatically gen-
erated with predefined structures like an analytical Jacobian to accelerate solving efficiency.
The default ODE solver “AutoTsit5(Rosenbrock23())” was chosen. This solver automati-
cally switches between a Runge-Kutta and Rosenbrock method depending on the stiffness
of the solution at the current time point.
2.2.4 Simulating LPS infection and Protein Knockdown
A callback event was used to dose the system with an impulse of LPS. When the sim-
ulation reaches a specified time point, the ODE solver is stopped, and the concentration of
LPS is changed to a nonzero value. This discontinuous jump is then used as a new initial
condition to continue the numerical simulation.
Knockdown simulations were performed in a similar fashion, but instead of changing a
state concentration, a parameter value was gradually reduced until it reached a value a zero.
At this point, the manipulated rate would be removed the simulation which corresponds to
a complete knock out of that reaction.
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2.2.5 Global Sensitivity Analysis
The DiffEqSensitivity.jl package was used to perform a global sensitivity analysis of the
system to determine which states were most impacted by changes in parameters. There
were multiple GSA methods available, but the eFAST (extended Fourier amplitude sen-
sitivity testing) method was selected for its robustness and speed. Briefly, eFAST is a
variance-based sensitivity analysis that assumes you have some model f with a set of inputs
x = {x1, x2, x3, ...xn} that generates and output Y [97]. The inputs in this case are the
different parameters and the output is a scalar value representing the simulation’s response
to the inputs. Here, the sum of the areas under each curve was used (other metrics like the
maximum concentration of a species are also valid, so long as the result is scalar). Without
loss of generality, we can treat each input as an independent, uniform random variable on
[0,1], and decompose the output Y as a sum of expected input values:
Y = f0 +
n∑
i=1
fi(xi) +
n∑
i<j
fij(xi, xj) + ...+ f1,2,...,n(x1, x2, ...xn), (2.1)
where f0 is the variance of the output (constant), fi(xi) is the variance of one input con-
ditioned on the output, fij(xi, xj) is the variance of two inputs conditioned on the output,
etc. By repeatedly sampling these expected values, we can estimate what proportion of the
input variances contributes to the total output variance. Differences between variance-based
sensitivity methods depend on how variances are estimated. The Sobol method uses Monte
Carlo integration to estimate expected values, whereas eFAST uses Fourier series expansion.
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2.3 Results
2.3.1 The Metabolic ODE Model Recapitulates Experimental Data
To compare this model against experimental data, a steady state solution needed to
be determined. Cells typically operate in a homeostatic range where the generation and
consumption of energy and molecules are in equilibrium. There are several ways to determine
a steady state solution, but the most straightforward method is to run the ODE simulation
until the derivative of each state is below some chosen threshold. Figure 2.3.1A depicts the
resulting steady states for each state in the system except for ATP and AMP. These species
were removed because their steady states were already known from literature. No LPS is
present in this system so the steady state values for LPS and active species in the PI3K.
Akt pathway are zero. ROS and SIRT6 possess substantially larger steady states when
compared to other signaling protein because of their production are large when compared
to their degradation rate. To ensure these values were a steady state solution, the system
what solved with this initial condition, and as demonstrated in Figure 2.3.1B every state
remained constant across the simulated time frame.
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Figure 2.3.1: Determining Metabolic Equilibrium. (A) The ODE is simulated from an arbitrary
initial condition until the derivative of each state is below the absolute tolerance of the ODE solver
(1 × 10−8). (B) The determined steady state is feed back into the ODE and simulated out for 24
hours. All states remain constant with respect to the error tolerance.
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Figure 2.3.2 shows how the simulation responds to changes in the AMP/ATP ratio. As
previous experimental data suggest [79, 98], increasing the proportion of AMP in the cell
should trigger the activation of AMPK through phosphorylation. Indeed, at t = 500 min,
AMPK phosphorylation does increase which triggers a signaling cascade to promote OX-
PHOS and restrict glycolysis. HIF-1 concentration decreases because SIRT6 is upregulated
and Rheb is deactivated. Interestingly, when the AMP/ATP ratio is decreased, the response
from AMPK is strengthened.
0 250 500 750 1000 1250
Time (min)
0.01
0.02
0.03
0.04
0.05
AM
P/
AT
P
AMP/ATP
0 288 576 864 1152 1440
Time (min)
0.04
0.06
0.08
0.10
0.12
[u
M
] AMPK(t)
AMPKp(t)
0 288 576 864 1152 1440
Time (min)
0.025
0.050
0.075
0.100
0.125
[u
M
]
CaMKII(t)
CaMKIIa(t)
0 288 576 864 1152 1440
Time (min)
0.0700
0.0725
0.0750
0.0775
0.0800
[u
M
] TSC2(t)
TSC2p(t)
0 288 576 864 1152 1440
Time (min)
0.042
0.044
0.046
0.048
0.050
0.052
0.054
[u
M
] Rheba(t)
Rheb(t)
0 288 576 864 1152 1440
Time (min)
0.06
0.07
0.08
0.09
[u
M
] mTORC1(t)
mTORC1_Rheba(t)
0 288 576 864 1152 1440
Time (min)
0
1
2
3
4
[u
M
]
SIRT6(t)
0 288 576 864 1152 1440
Time (min)
0.025
0.050
0.075
0.100
0.125
[u
M
]
HIF1a(t)
HIF1(t)
0 288 576 864 1152 1440
Time (min)
0.00
0.05
0.10
0.15
[u
M
]
LPS(t)
TLR4(t)
TLR4_LPS(t)
0 288 576 864 1152 1440
Time (min)
0.00
0.05
0.10
0.15
[u
M
]
PI3K(t)
PI3Ka(t)
0 288 576 864 1152 1440
Time (min)
0.00
0.05
0.10
0.15
[u
M
]
Akt(t)
Aktp(t)
0 288 576 864 1152 1440
Time (min)
0
1
2
3
4
[u
M
]
ROS(t)
Figure 2.3.2: Modulating AMP/ATP Ratio. Here the AMP/ATP was manipulated to determine
if the system would respond similarly to experiment data. At t = 500 min, the amount of AMP was
increased by 200 µM and ATP was correspondingly decreased by the same amount. The reverse
was scenario was performed at t = 1000 min by decreasing the amount of AMP in the cell.
2.3.2 Biphasic Metabolic Shifting is Dependent on LPS clearance
To determine how the system behaves when introduce to LPS, the steady state system
in Figure 2.3.1 was modified with a dose callback event. At t = 250 min, this callback event
is trigger and modifies the current LPS concentration from zero to 0.05 µM . This would
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be equivalent to a cell receiving an LPS injection in vitro, where the concentration of the
stimulant suddenly increases.
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Figure 2.3.3: LPS Impulse Response. The stabilized ODE model was dosed with LPS at t = 250
min. LPS quickly binds to TLR4 and degrades, allowing the system to return to steady state.
Figure 2.3.3 illustrates the dynamic response after LPS dosing. Immediately following
LPS introduction, the amount of free LPS decreases as it binds to TLR4, forming a complex.
This subsequently activates the PI3K/Akt pathway to inhibit TSC2 phosphorylation. This
allows mTORC1 activity to rise and finally increase HIF-1. Of note, because HIF-1 is used
as an indicator for glycolysis, it slightly increases the amount of ATP in the system (thus
decreasing the AMP/ATP ratio). This change is small because the ATP production rate
of glycolysis is about 10 times smaller than OXPHOS. This slight increase in ATP has the
minuscule effect of lowering AMPKp activity. Nevertheless, the simulation is emulating a
cell utilizing OXPHOS, transitioning to a glycolytic state, and reverting back to OXPHOS.
35
0
25
0
50
0
75
0
10
00
12
50
Time (min)
267.5
270.0
272.5
275.0
277.5
280.0
M
AMP
0
25
0
50
0
75
0
10
00
12
50
Time (min)
9600.0
9602.5
9605.0
9607.5
9610.0
9612.5
M
ATP
0
25
0
50
0
75
0
10
00
12
50
Time (min)
0.0384
0.0387
0.0390
0.0393
0.0396
M
AMPK
0
25
0
50
0
75
0
10
00
12
50
Time (min)
0.1104
0.1107
0.1110
0.1113
0.1116
M
AMPKp
0
25
0
50
0
75
0
10
00
12
50
Time (min)
5.52×10 3
5.54×10 3
5.56×10 3
5.58×10 3
M
CaMKII
0
25
0
50
0
75
0
10
00
12
50
Time (min)
1.4442×10 1
1.4444×10 1
1.4446×10 1
1.4448×10 1
M
CaMKIIa
0
25
0
50
0
75
0
10
00
12
50
Time (min)
0.08
0.09
0.10
0.11
M
TSC2
0
25
0
50
0
75
0
10
00
12
50
Time (min)
0.04
0.05
0.06
0.07
M
TSC2p
0
25
0
50
0
75
0
10
00
12
50
Time (min)
0.057
0.060
0.063
0.066
M
Rheba
0
25
0
50
0
75
0
10
00
12
50
Time (min)
0.025
0.030
0.035
0.040
M
Rheb
0
25
0
50
0
75
0
10
00
12
50
Time (min)
0.090
0.092
0.094
0.096
M
mTORC1
0
25
0
50
0
75
0
10
00
12
50
Time (min)
0.054
0.056
0.058
0.060
M
mTORC1_Rheba
0
25
0
50
0
75
0
10
00
12
50
Time (min)
2.59
2.60
2.61
2.62
M
SIRT6
0
25
0
50
0
75
0
10
00
12
50
Time (min)
0.0180
0.0185
0.0190
0.0195
0.0200
0.0205
M
HIF1a
0
25
0
50
0
75
0
10
00
12
50
Time (min)
0.130
0.135
0.140
0.145
M
HIF1
0
25
0
50
0
75
0
10
00
12
50
Time (min)
0.00
0.02
0.04
0.06
0.08
M
LPS
0
25
0
50
0
75
0
10
00
12
50
Time (min)
0.10
0.11
0.12
0.13
0.14
0.15
M
TLR4
0
25
0
50
0
75
0
10
00
12
50
Time (min)
0.00
0.01
0.02
0.03
0.04
0.05
M
TLR4_LPS
0
25
0
50
0
75
0
10
00
12
50
Time (min)
0.10
0.11
0.12
0.13
0.14
0.15
M
PI3K
0
25
0
50
0
75
0
10
00
12
50
Time (min)
0.00
0.01
0.02
0.03
0.04
0.05
M
PI3Ka
0
25
0
50
0
75
0
10
00
12
50
Time (min)
0.10
0.11
0.12
0.13
0.14
0.15
M
Akt
0
25
0
50
0
75
0
10
00
12
50
Time (min)
0.00
0.01
0.02
0.03
0.04
0.05
M
Aktp
0
25
0
50
0
75
0
10
00
12
50
Time (min)
2.59
2.60
2.61
2.62
M
ROS
Knock Down %
100%75%50%25%0%
Figure 2.3.4: Effect of LPS Clearance on Metabolic Reprogramming. The ODE system was dosed
with LPS at t = 250 min, but now with the added effect of varying LPS degradation (τ16). The
value of τ16 is simulated at its original value (0% knockdown, blue line) all the way to a complete
knockout (100% knockdown, red line) where τ16 = 0.
.
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LPS was given an artificial degradation rate (τ16) to provide the cell a means to clear the
stimulus. This would be synonymous to washing cells in culture after stimulation with LPS.
If this degradation rate parameter is reduced, the system can be simulated with progressively
more prolonged doses of LPS. Figure 2.3.4 shows the same simulation from Figure 2.3.3, but
with the addition of progressively lowering the degradation rate by the given percentage. At
50%, for example, the value of τ16 is halved and at 100% is set to a value of zero. Without the
ability to clear the LPS signal (100% knock-down, red line), HIF-1 and AMPKp transition
to a new equilibrium where HIF-1 levels have increased and AMPKp levels have decreased.
This signifies a transition in metabolism to aerobic glycolysis and away from OXPHOS.
In addition to this permanent trade-off in metabolism, these simulations show a decrease
in the AMP/ATP ratio (or equivalently and increase in ATP levels). This accumulation in
energy supply could be and indicator for cells preparing to enter a resistive immune state,
which would necessitate higher ATP levels.
2.3.3 Global Sensitivity Analysis Reveals AMPK insensitivity
Sensitivity analyses are an excellent tool for characterizing what parameters are con-
tributing most significantly to changes in the ODE states. Figure 2.3.4 illustrates the results
from performing an eFAST global sensitivity analysis. This simulation included a callback
to trigger an LPS dosing at t = 250 min. Without this stimulation, the sensitivity values for
the PI3K/Akt pathway would all remain at zero.
One interesting observation from this analysis is how insensitive glycolytic ATP produc-
tion (k1bf ) is compared to OXPHOS (k1af ) or the basal consumption rate (k1r). It appears
that only SIRT6 exhibits some sensitivity to glycolysis, which is not surprising because it
directly inhibits this process. Oddly, activated mTORC1 is insensitive to glycolysis despite
directly promoting its activation.
The most sensitive species/parameter combination was LPS and its associated degra-
dation constant. In fact, LPS shows no sensitivity toward any other parameter, which is
appropriate as LPS acts as an input to the system.
37
k1
af
k1
bf k1
r k2
f
k2
r k3
f
k3
r k4
f
k4
r k5
f
k5
ar
k5
br k6
f
k6
r k7
f
k7
r k8
f 8 k9
f 9
k1
0f
k1
0r 11 k1
2f
k1
2r k1
3f
k1
3r k1
4f
k1
4r k1
5f 15 16
Parmerter
AMP
ATP
AMPK
AMPKp
CaMKII
CaMKIIa
TSC2
TSC2p
Rheba
Rheb
mTORC1
mTORC1_Rheba
SIRT6
HIF1a
HIF1
LPS
TLR4
TLR4_LPS
PI3K
PI3Ka
Akt
Aktp
ROS
Sp
ec
ie
s
Total Order Global Sensitivity
0.2
0.4
0.6
0.8
Se
ns
iti
vi
ty
Figure 2.3.5: eFAST Global Sensitivity Analysis. Normalized sensitivities are calculated for each
parameter/species combination. A darker color indicates that small perturbations in the parameter
lead to large changes in the associated protein/molecule. The parameters were allowed to range
between half and double their original values.
The least sensitive parameters are k2f , k2r, k3f , and k3r. These parameters control
the AMPK/AMPKp activation level directly or indirectly through CaMKII. As observed in
Figure 2.3.3, the magnitude AMPKp is not significantly impacted by LPS dosing because
HIF-1 has a smaller effect on the AMP/ATP ratio. CaMKII activity changes with ROS
concentration, a byproduct of OXPHOS and directly affected by AMPKp. CaMKII activity
is sensitive to ROS through the k15f and τ15, but this sensitivity is not an adequate to impact
AMPK downstream.
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2.4 Summary
Sepsis is a complex, multi-organ condition that causes detrimental, and even fatal out-
comes. Even with proper treatment and early detection, sepsis still remains a leading cause
of death in the United States and is responsible for being the most common cause of death
in the ICU [99]. We have spent decades trying to discover potential treatments to combat
these morbid outcomes by most fail clinical trial [8]. To investigate therapies that go beyond
anti-inflammation strategies, we need to develop a comprehensive, systems level perspective
of how sepsis impacts the body. Recent studies have shown that, in addition to elevating the
immune response, sepsis is responsible for cells shifting their metabolic state from oxidative
phosphorylation to aerobic glycolysis. The goal of this aim was to develop a computational
algorithm that demonstrates how this metabolic reprogramming occurs and determine suffi-
cient conditions that cause metabolism to shift back. The model was able to show how LPS
stimulation resulted in the deactivation of TSC2 which leads to an increase in glycolysis. It
also predicts that biphasic shift is possible if LPS can be cleared from the cell (Figure 2.3.4).
Jin et. al. published a study this year investigating the role of AMPK activity in
the renal metabolic response to sepsis. In their experiments, cells were given “inflammatory
mix” (IM)— a combination LPS and other damage associated molecular patterns to emulate
sepsis— and measured for AMPK activity over time. They observed an increase in AMPK
activity within the first five minutes of treatment followed by a gradual decline in the next
hour. Then, at later time points (2, 6, 12, 18, and 24 hours) under the same condition,
AMPK activity began to recover. Our model predicts this gradual decrease and eventual
recovery if LPS is being cleared from the cell. It fails to predict the immediate increase in
AMPK activity which may indicate some unknown mechanism between LPS and AMPK.
As the model is defined, triggering a septic episode appears to increase the amount of
ATP produced by glycolysis, but because its contribution was already low, OXPHOS is
not significantly inhibited. What emerges from this simulation is a scenario where both
OXPHOS and are glycolysis are utilized, decreasing the AMP/ATP ratio (Figure 2.3.3).
This heightened energy state is sustained if LPS remains in the cell (Figure 2.3.4) and is due
to a lack of sensitivity in subtle AMP/ATP fluctuations from AMPK (Figure 2.3.4). This
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possible co-activation, as opposed to full shift, would need to be experimentally confirmed.
One possible experiment design would involve performing OCR and ECAR measurements
across mutliple time points to determine the contribution of ATP production from each
metabolic pathway.
This computational model comes with some limitations that deserve mention. The first
is the lack of dynamic data to inform the model. This is a common problem in systems
biological as dynamic information is difficult to measure experimentally (especially without
sacrificing the cells to make the measurement). While the predicted trends from these
simulation match experiments in a qualitative manner, further work needs to be done to
integrate these data into the model. Another limitation related to this is obtaining absolute
concentration measurements to inform the initial conditions. This is less concerning though
because the ODE model can be easily re-scaled to match these measurements (if there exists
an accessible method to determine these values).
Overall, this model demonstrates a simple and user-friendly methodology to generate an
ODE model from a given network of interconnected signaling pathways. Advanced model
perturbations and analyses were utilized to stabilize the model at a steady state and gain
insight into how the system behaved. Using these tools, we were able to confirm the plausi-
bility of a metabolic shift and demonstrate sufficient conditions to cause the (small) shift to
reverse. By incrementally building on our knowledge of sepsis and metabolism, we hope to
identify and simulate new potential treatments to improve patient outcome.
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3.0 Mathematical Modeling of the cGAS Pathway Reveals Robustness of
DNA Sensing to TREX1 Feedback
3.1 Introduction
The Cyclic GMP-AMP synthase (cGAS) pathway represents a critical component of the
innate immune system that is responsible for detecting dangerous changes in the intracellular
environment and maintaining organismal homeostasis. In healthy nondividing cells, DNA is
located in the mitochondria and nucleus, so accumulation of DNA in the cytosol typically
indicates a breakdown in organelle stability (e.g. tumorigenesis [28, 100] or the presence of
a pathogen [101, 102, 103, 104, 105, 106, 107, 108]). While the cGAS pathway must rapidly
detect cytosolic DNA and effectively coordinate an immune response, aberrant activation
can lead to autoimmune and inflammatory disease [109, 110, 111]. The use of computational
tools to model the cGAS pathway can reveal insights about immune regulation and identify
unexpected systems-level emergent behaviors that result from changes in the intracellular
environment, such as chronic inflammation. Cytosolic DNA is primarily detected by the
DNA sensing molecule, cGAS [24]. cGAS and DNA bind to form an activated enzyme
complex which triggers a series of molecular interactions culminating in the production of
type I interferons (IFNα/β). Studies have confirmed that cGAS is the primary cytosolic
DNA sensing molecule for a large variety of pathogens, including DNA-containing viruses
(herpes simplex virus [108], adenovirus [105]), retroviruses (HIV [102]), and bacteria (L.
monocytogenes [104], M. tuberculosis [101, 107]). There is also evidence of viruses actively
inhibiting cGAS pathway activity to promote virus replication. In the case of poxviruses
(e.g. smallpox), cGAS is able to bind to viral DNA, but the downstream signaling protein
stimulator of interferon genes (STING) is inhibited by the virus, preventing its dimerization
and phosphorylation [103]. This example demonstrates the complex relationship between
the cGAS pathway and the pathogens it defends against.
cGAS is known to bind to self-DNA that has leaked from the nucleus of damaged cells
[112, 113]. This DNA leakage is an early indicator of tumorigenesis in cancer and can be
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detected by the cGAS pathway. Interestingly, prolonged activation of the cGAS pathway
has been shown to cause inflammation-mediated tumor growth [28], bringing into question
the viability of immunomodulatory treatments that promote cGAS activity to regulate tu-
morigenesis. Dysregulation of the cGAS pathway can lead to impaired immunity or chronic
inflammation. A well-established example of this impairment is Aicardi–Goutie`res syndrome
(AGS) [110], an autoimmune disorder where the DNA degradative enzyme three prime repair
exonuclease 1 (TREX1) is nonfunctional in its role as a suppressor of the cGAS pathway.
This disorder is characterized by elevated interferon levels and chronic inflammation. The
cGAS pathway has also been associated with more prevalent autoimmune diseases, such as
lupus erythematosus [30], and age-related diseases, such as atherosclerosis and neurodegen-
erative diseases [32]. With extensive connections to innate and adaptive immunity. as well
as various diseases and pathogens, it is critical to develop a systems-level understanding of
how the cGAS pathway dynamically regulates the immune response.
To investigate the regulation of the cGAS pathway, mathematical models can be con-
structed using principles from the fields of reaction kinetics and transport phenomena to
capture system-wide dynamic responses. Comprehensive molecular interaction maps of im-
mune signaling pathways have been published [114, 115], however, little is known about
the expectant system dynamics under different biological conditions. Elucidating these dy-
namics can be problematic as data most often only provides a snapshot of a specific event.
To mitigate this problem, systems biology approaches are implemented to interpolate the
dynamics between static observations [38, 116]. Specifically, ordinary differential equations
(ODEs) constructed from mass and energy conservations are employed to track the species’
concentrations within a cell over time. This method has demonstrated significant success in
describing complex dynamics for a variety of signaling pathways. Key examples include ex-
plaining the appearance of robustness within a system [117, 118, 119], oscillatory properties
of circadian rhythms [120] and the NF-κB pathway [40], and switch mechanisms that give
rise to all-or-nothing responses to stimuli [121].
In this study, we introduce an ODE model to quantify cGAS pathway activity and assess
the model’s robustness to parametric uncertainty in the feedback components that primarily
regulate the pathway’s dynamics. Conservation of mass principles were used to construct
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the ODE description of the cGAS pathway kinetics and enzyme reactions were modeled
with Michaelis Menten kinetics. To capture paracrine and autocrine signaling effects, IFNβ
responses predicted from the cGAS pathway model were used as inputs into an existing
model of the janus kinase/ signal transducer and activator of transcription (JAK/STAT)
pathway which simulates IFNβ regulation via the IFN receptor [122]. Additionally, Three
Prime Repair Exonuclease 1 (TREX1), a known DNase and interferon stimulated gene (ISG),
was recently shown to be essential for degrading cytosolic DNA when the cGAS pathway
was activated and was included in the model [110, 123]. A literature search was performed
to compile experimental data and fit model parameters to biologically relevant ranges [124,
125, 126, 127, 128, 24, 129]. Applying this model, we test how robust the relative timing
and intensity of the IFN response is to perturbations in TREX1 and interferon regulatory
transcription factor 7 (IRF7) feedback and compare model predictions to data observed in a
drug inhibition study. We find the model to be extremely robust to perturbations in TREX1
activity, but susceptible to changes in IRF7 activity.
3.2 Materials and Methods
3.2.1 Model Construction
As shown in Figure 3.1.1, the cGAS pathway regulates type I interferon production
through the JAK/STAT pathway. The cGAS pathway consists of 7 states summarizing
how DNA is detected in the cytosol to produce the initial interferon response (see equa-
tions 1-7 in Appendix A.1). This pathway begins with cGAS reversibly binding to cy-
tosolic double stranded DNA and enzymatically producing 2’-3’-cyclic guanosine monophos-
phate–adenosine monophosphate (cGAMP) [130, 24]. The enzymatic activity of cGAS is
assumed to be saturated as the basal concentrations of ATP and GTP are orders of magni-
tude higher relative to cGAS [131, 132]. The produced secondary messenger cGAMP diffuses
to the endoplasmic reticulum (ER) and reversibly binds to STING [133, 134], which is mod-
eled using mass action kinetics. This binding induces a conformational change in STING
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Figure 3.1.1: Diagram illustrating the components of the cGAS and JAK/STAT pathways. Host
or pathogenic DNA enters the cytosol and is bound to cGAS, activating the enzymatic conversion
of ATP and GTP to cGAMP. The secondary messenger cGAMP binds to STING which undergoes
a conformational change releasing it from the ER. STING trafficks to the perinuclear space and acts
as a scaffolding protein to allow for the phosphorylation of IRF3. This complex enters the nucleus
and acts as a transcription factor for IFNβ. Translation of IFNβ initiates the JAK/STAT pathway
through autocrine (shown here) and paracrine signaling. Through the formation of STAT com-
plexes, this pathway activates positive (IRF7) and negative (SOCS, TREX1) feedback mechanisms
to regulate the whole system. Systems equations, state descriptions and parameter descriptions are
in Appendix A.1
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releasing it from the ER and allowing it to migrate to the ERGIC [25]. Here it acts as a
scaffolding protein to aid in the phosphorylation of interferon regulatory transcription factor
3 (IRF3). Phosphorylated IRF3 then reversibly dimerizes and enters the nucleus to tran-
scribe IFNβ. The entire process of IRF3 phosphorylation and dimerization was lumped into
a Michaels Menten model to minimize the number of parameters necessary to describe the
interaction. This method simplifies the model but neglects nonlinear terms associated with
IRF3 dimerization. The promoter region of IFNβ is controlled by four positive regulatory
domains [36], but it was assumed modeling one (IRF3) would sufficiently recapitulate IFNβ
dynamics.
A model describing the JAK/STAT pathway [122] that captured the type I interferon
response in influenza infected cells was modified to include the cGAS pathway. The initial
JAK/STAT model was unstable. Unstable models cannot capture critical signaling features
such as time until system shut down and transitions between steady states. Therefore, the
JAK/STAT model was altered and parameterized simultaneously with the complete ODE
model system. Specifically, degradation rates were introduced to prevent unbounded pro-
duction [135, 136, 137] and the piecewise differential equation for phosphorylated Interferon
Regulatory Factor 7 (IRF7) was removed and replaced with a mass action rate equation.
Additionally, the combined model in this paper makes no distinction between subtypes of
type I interferon, so any dynamics involving IFNα were removed.
The modified JAK/STAT model adds an additional 6 states to describe how IFNβ pro-
tein promotes the dimerization and phosphorylation of STAT and subsequently induces the
transcription of ISGs (see AppendixA.1, EquationsA.8 -A.13). The pathway begins with the
activation of interferon-α/β receptor (IFNAR) by IFNβ and leads to the synthesis of STAT
complexes which can be inhibited by the presence suppressor of cytokine signaling (SOCS)
proteins. Both STAT and SOCS proteins have different subtypes (e.g. SOCS1, STAT2),
but no distinction is made between these for the sake of model simplification. Moreover,
a quasi-steady state assumption was implemented by Qiao et. al. to directly relate the
amount of SOCS mRNA to its protein. The STAT complex enters the nucleus and promotes
the transcription of SOCS and IRF7 which in turn activates negative and positive feedback
loops, respectively. Other ISGs are transcribed but are assumed to have no effect on the dy-
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namics of the pathway. The stability of DNA molecules necessitates a regulatory mechanism
for active degradation. A TREX1 double knockout study in mice suggests that TREX1 is
the primary DNase that degrades cytosolic DNA in response to cGAS activation [110]. Also,
evidence suggests that TREX1 is an interferon stimulated gene and it is therefore regulated
by IFNβ in the model [123, 138].
In total, the model is comprised of 13 states whose dynamics are described by 34 pa-
rameters separated into three groups: cGAS pathway parameters (13 total), JAK/STAT
parameters (11 total), and degradation rate parameters (10 total). It was assumed that
none of the cGAS pathway or JAK/STAT parameters were known, and TREX1 negative
feedback activation was also unknown. Additionally, one degradation rate was not found in
literature, leading to a total of 25 unknown parameters to be optimized.
3.2.2 ODE Simulation
The Advanced MATLAB Interface for CVODES and IDAS (AMICI) toolbox was used to
simulate the ODE model. Using symbolic notation in MATLAB, states (species), parameters,
and rate equations were written and converted into compiled C code for efficient simulation.
AMICI utilizes SUNDIALS to simulate the complied model by implementing a variably stiff
ODE solver to numerically estimate the ODE solution.
3.2.3 Markov Chain Monte Carlo (MCMC) Optimization
Many MCMC methods are available to perform parameter optimization but based on
a recent review by Ballnus [43] we chose to use the toolbox PESTO to implement a paral-
lel tempering (PT) MCMC algorithm in conjunction with a multi-start local optimization.
Briefly, PESTO begins by using an interior-point minimization routine in MATLAB (fmin-
con) initialized from 1,000 randomly distributed starting points. These starting points are
determined using Latin Hypercube Sampling. PT MCMC then uses these local minima and
gradient information to initialize the algorithm. Both methods have been shown to greatly
improve convergence to a stationary distribution over single chain methods initialized by the
prior distribution. Local optimization is also designed to significantly reduce burn-in time.
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To further increase the likelihood convergence, PT MCMC ran for 10 million iterations and
was repeated in triplicate (labeled as Runs 1-3 in the Results and Discussion).
3.2.4 Data Compilation
To perform the MCMC optimization, data procured from literature was used to inform
the unknown model parameters (Supplementary File 1). This data is comprised of 10 unique
time course experiments using RT-qPCR and Western blots techniques to measure 7 of the 13
states simulated in the model. Neither of these techniques allow for absolute quantification
of concentration, so data were normalized to be bounded on [0,1] and thus provide a measure
of the response dynamics but not the magnitude of the responses. Ideally, data would come
from a single cell type, but dynamic data for cGAS activation was limited. We collected
data from monocytes, macrophages, and fibroblasts. Pulling data from these cell types was
justified as (1) monocytes, macrophages, and fibroblasts all are strong interferon producers
and (2) demonstrated similar IFNβ and IRF3 dynamics [139].
Table 1: Compilation of Experimental Data
Experiment Measured State Label Reference Stimulant Cell Line Cell Type
1 IFNβ m Sun [24] HT-DNA L929 Fibroblast
2 IFNβ m Stanley [124] LPS BMDM Macrophage
3 IFNβ m Stanley [124] TB BMDM Macrophage
4 IFNβ Guo [125] cGAMP BMDM Macrophage
5 IRF3c Sun [24] HT-DNA THP1 Monocyte
6 SOCS1m Posselt [127] LPS moDC Monocyte Derived Dendritic Cell
7 IRF3c Wang [129] HT-DNA L929 Fibroblast
8 STINGc Jønsson [126] dsDNA THP1 Monocyte
9 IRF3c Jønsson [126] dsDNA THP1 Monocyte
10 IRF7m Qing [128] poly (I:C) MEF Fibroblast
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3.2.5 Objective function formulation
To inform the MCMC algorithm, a likelihood function based on a sum-of-squares error
(SSE) function was developed:
SSE =
Sm∑
i=1
T∑
i=1
(Nij −Oij)2
Pj
+
S∑
k=1
(
1− Mk
Dk
)2
. (3.1)
The objective function is separated into two components: the left component evaluat-
ing the fit of the systems dynamics when all data and state values are normalized to be
[0,1] and the right component evaluating the peak concentrations of each species. The error
comparing normalized observations (Oij) and normalized simulations (Nij) is weighted by
the number of available data points (Pj) to deprioritize experiments with a large number of
observations. The error between simulation magnitude (Mk) and desired magnitude (Dk)
allows us to identify solutions in which the maximal concentrations are within or near bio-
logically relevant ranges [96]. Here magnitude refers to the absolute maximum or minimum
concentration achieved by a particular species. Most of the species are initiated at a con-
centration of zero and reach a maximum concentration at some time after DNA stimulation.
In contrast, species with non-zero initial conditions achieve a minimum concentration as
the simulation progresses. This minimum achieved concentration was optimized to a value
80% of the initial condition. One exception to this was DNA. The model shows DNA con-
centration monotonically decreasing over time meaning it does not achieve a maximum or
minimum concentration. For this reason, it was excluded from this portion of the objective
function. The model error is summed over all observed time points (T) for a given measured
species (Sm) and the magnitude errors are summed over all observed species (S). Note that
Sm represents species with observations and is a subset of S. The negative log likelihood
was determined directly from the total sum-of-squares error (SSE) for each parameter set
evaluated and was used by the MCMC algorithm to sample the posterior.
3.2.6 MCMC Diagnostics
To determine if the MCMC algorithm was successful in sampling posterior parameter
distributions, several diagnostics were performed (see Appendix Figures A.2.1,A.2.2,A.2.3).
48
None of these tests give definitive proof for convergence but do provide an understanding
of the overall health of the MCMC run. Three different diagnostics were performed in
total. The first examines the acceptance rate of a new parameter value after each iteration.
Ideally, the acceptance rate should be held at 23% [44]. The second diagnostic considers
the autocorrelation which ensures PESTO is taking independent parameter samples. With
high correlation the resulting effective sample size is severely reduced meaning the MCMC
algorithm would have to be run for longer to obtain the same number of independent samples.
The last test is the Gelman-Rubin diagnostic [45] which compares multiple independent runs
to determine convergence. All diagnostics were performed using the “coda” R package [140].
3.2.7 Sensitivity Analysis
To evaluate parameter sensitivities on different states within the model over the simulated
time, the AMICI toolbox was again utilized. The normalized local sensitivity was calculated
as follows:
Sensitivity =
(
k
x(t)
)(
∂x(t)
∂k
)
, (3.2)
here, the sensitivity of state x(t) to the parameter k is shown. The normalization in front of
the derivative allows for a better comparison between states [141].
3.2.8 Simulated Drug Inhibition of cGAS
A recent paper by Vincent et. al. [142] demonstrated the viability for small molecule
drug interference of cGAS through competitive inhibition of cGAMP formation. To assess
the applicability of our ODE model to emulate drug-mediated cGAS dynamics, we intro-
duced two species: Drug and cGASn. Drug is a generic name for the small molecule capable
of reversibly binding to the DNA:cGAS complex. That binding event produces cGASn,
a drug bound cGAS molecule with no enzymatic activity. The binding event was simu-
lated using first order mass action kinetics requiring both forward (kon) and reverse (koff )
rate constants (see AppendixA.1, EquationsA.14 -A.16). These rates constants were unique
for each drug and constrained by their experimentally determined disassociation constants
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(Kd = koff/kon). One of the three drugs (RU.332) did not have an experimentally esti-
mated Kd value and was excluded from the analysis. The remaining two drugs (RU.365 and
RU.521) were utilized in the analysis.
Data from drug dose response curves reported in Vincent et. al. showing IFNβ activation
were used to parameterize model simulations. The model was simulated across different drug
concentrations and the maximum IFNβ concentration was recorded. To optimize kon and
koff , the data and model responses were normalized between zero and one and MATLAB’s
patternsearch function was used to minimize the sum-of-squares error. Additionally, a non-
negative boundary was set on kon and koff to further constrain the solution space.
To compare experimental IC50 values (which were previously determined through non-
linear fitting by Vincent et. al.) to our model estimated IC50 values, MATLAB’s fzero
function was used to calculate what drug concentration resulted in half of the maximum
IFNβ expression simulated. Absolute error was then calculated to compare experimental
and model determined IC50 values.
3.3 Results
3.3.1 An Experimentally Informed ODE model Emulates the cGAS pathway
We sought to develop a model of the cGAS pathway that could explain previously pub-
lished experimental data, and by applying a multi-start MCMC algorithm several times, we
observed two distinct parameterizations that fit known pathway responses. The resulting
dynamics of those parameterizations can be seen in Figure 3.3.2 where we plot the time
profiles for each species for the top 1000 parameterizations (instances) identified in three
MCMC parameterizations (labeled as runs 1-3). Overall, the dynamics of each species re-
main similar in both timing and magnitude for the different parameterization runs except for
DNA. For runs 1 and 3, a delay between DNA binding and TREX1 degradation is observed
as DNA concentration stagnates for several hours. In run 2, there is steep decline in DNA
concentration—likely due to the lack of knowledge of the rate of DNA degradation. Testing
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Figure 3.3.1: Model Parameter Distributions
the validity of either prediction experimentally would provide a greater understanding of the
dynamics regulating cytosolic DNA.
Despite differences in the apparent dynamics, the top 1000 parameterizations from each
run equally minimized the objective function (Equation 3.1). After 10 million iterations of
the MCMC algorithm, the absolute difference in error between each run was at most 4×10−4
(unitless). As illustrated in Figure 3.3.3, the convergence of the MCMC algorithm occurred
after approximately 1 million iterations after which only minor changes in the objective
function were observed. To determine the relative error contribution provided by each of
the components of the objective function, we separately plotted the dynamic and peak error
as defined by Equation 1 (see Appendix Figure A.2.4). Here we observe the error for each
component is on the same order of magnitude meaning both offer significant contributions
to the overall error.
We next examined the parameter distributions obtained from the MCMC traces ( Ap-
pendix Figure A.2.5) for the 3 parameterized runs. In Figure 3.3.1 we report summary
statistics of the parameter distributions obtained after burn-in for the last 1 million instances
per run and confirm differences in parameterization from the second MCMC run. Appendix
Figure A.2.6 shows the complete parameter distributions obtained after 1 million MCMC
instances post burn-in. Major deviations are observed in k1f and k1r (cGAS/DNA binding)
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as well as kcat2 and Km2 (DNA degradation) explaining differences observed in DNA dy-
namics (Figure 3.3.2). Some parameters (k11f, k10f1, and k12f) were pushed to boundaries
set before optimization and shifting these boundaries resulted in integration errors; there-
fore, conclusions concerning these parameters are limited. For all follow-up analyses of the
model (and for the trajectories shown in Figure 3.3.2), we restricted our analyses to the top
1000 parameter sets for each run (3000 sets total). To ensure this parameter subset accu-
rately sampled the total distribution determined by MCMC after burn-in, we compared these
distributions against each other and observed sufficient agreement (Appendix Figure A.2.7).
Figure 3.3.2: Trajectories of the top 1000 Parameterizations.
In addition to parameter distributions, we also investigated parameter correlations (Ap-
pendix Figure A.2.8) and observed identical correlations for runs 1 and 3, but differences
in run 2. Common to all runs was a strong correlation between some Michaels Menten
parameters (kcat5/Km5, kcat6/Km6, kcat7/Km7, and kcat8/Km8) and mass action param-
eters (k4f/k4r) suggesting structural non-identifiability. Looking at differences between the
separate runs we note high correlation in the kcat2 and Km2 parameters (associated with
TREX1) to k1f, k3f, and k3r (associated with cGAMP) only for run 2. A strong correlation
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was also observed exclusive to runs 1 and 3 between k1f and k1r to k4f and k4r. These
correlations suggest identifiability issues specific to that parameterization. To alleviate these
run specific problems more data would be needed for parametrization.
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Figure 3.3.3: Error function: MCMC Performance
3.3.2 Sensitivity analysis reveals IFNβ, cGAMP, and TREX1 to be sensitive to
parameter perturbations
As MCMC produces ensembles of models capable of fitting relevant data, we selected the
top 1000 models identified in each MCMC run (same ensembles as those in Figures 3.3.2) and
performed a local sensitivity analysis to identify the most influential processes. To summarize
the results of this analysis, we calculated the mean maximum sensitivity achieved for each
state in each of the 1000 models across the three independent MCMC runs (3000 model
parameterizations in all). Figure 3.3.4 shows the results for all states exhibiting significant
parametric sensitivity (see Appendix Figure A.2.9 for all species). Error bars represent the
range of maximum sensitivity obtained over all iterations. Comparing the different MCMC
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runs we find that all three runs follow similar trends but the absolute magnitude of sensitivity
for the second run is lower for most of the parameters. This suggests that differences in
sensitivity between parameters are determined by model architecture and independent of
the specific parameter value.
Figure 3.3.4: Sensitivity Analysis. Represented are the three most sensitive species found in the
ODE model. Each dot represents the mean maximum sensitivity determined by the AMICI toolbox
across the 1000 instances. The error bars show the range of maximum sensitivity found for the top
1000 parameter sets for each run.
IFNβ, TREX1, and cGAMP are most sensitive to parametric uncertainty and are gener-
ally affected by processes which directly affect their activity. IFNβ has the largest negative
sensitivity with its degradation rate (τ7) and shows the strongest positive sensitivity with
the translation of IFNβ mRNA (kcat7). The sensitivity analysis also reveals that IFNβ was
insensitive to the SOCS feedback mechanism (k8f and k9f) and was primarily regulated
through its degradation rate constant (τ7). This result suggests that the model is insen-
sitive to uncertainty in this feedback mechanism to accurately describe system dynamics.
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cGAMP exhibited the second highest overall sensitivity to parametric uncertainty, showing
positive sensitivity to STING:cGAMP complex formation (k3f) and negative sensitivity to
the unbinding of cGAS and DNA (k1r). Finally, TREX1 is the only other species that
showed significant sensitivity to optimized parameters. The highest positive sensitivity was
seen from the translation of IRF7 mRNA (k12f) and showed no single significant negative
sensitivity. This positive sensitivity suggests that perturbations or uncertainties in the posi-
tive feedback mechanism involving IRF7 impacts the negative feedback of TREX1 regulated
DNA degradation.
3.3.3 Inhibition of TREX1 activity demonstrates robustness to a chronic in-
flammatory state
Next, we simulated an in-silico knock-down simulation of TREX1 to determine the ro-
bustness of IFNβ activation from partial to full inhibition of TREX1 activity. Aberrant
activation of the cGAS pathway has been demonstrated to lead to autoimmune diseases like
Aicardi-Goutieres syndrome (AGS) and Systemic lupus erythematosus (SLE) and a lack of
or inhibited activity of TREX1 has been suggested as the cause [110]. Knock-down was
simulated by varying the kcat2 parameter responsible for the degradation reaction between
DNA and TREX1. Figure 3.3.5 shows a representative sample of the simulated knock-down
for the top 1,000 parameter sets from Runs 1 and 2 (Run 3 results are redundant with Run
1). With both runs, IFNβ levels are strongly robust to partial inhibition but demonstrate
sustained IFNβ levels at 100% inhibition. Complete loss of function is necessary to induce
a chronically inflamed state. Some major deviations in dynamics are observed between run
1 and run 2. Run 1 (Figure 3.3.5a) shows a higher steady state value for cGAS and DNA
than Run 2 (Figure 3.3.5b) by 0.15 nM (25% difference). These differences in steady states
are a result of the different parameterizations discussed above.
In addition to simulating TREX1 knock-down, IRF7 knock-down was also performed.
Figures 3.3.5c (runs 1 and 3) and 3.3.5d (run 2) show knock-down of IRF7 activity by
modifying the k12f parameter responsible for IRF7 translation. Contrary to TREX1 knock-
down, IFNβ and TREX1 concentrations were not robust to changes in IRF7 activity. IRF7
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knock-down has no impact on upstream species (e.g. DNA and cGAS), but reduction does
lead to faster dissipation of IFNβ. This is expected as IRF7 is a transcription factor for
IFNβ. In sum, the key observation is that partial inhibition of TREX1 has no impact IFNβ
activity, whereas IRF7 inhibition induces changes in IFNβ activity.
(a) Run 1: TREX1 Knock-down (b) Run 2: TREX1 Knock-down
(c) Run 1: IRF7 Knock-down (d) Run 2: IRF7 Knock-down
Figure 3.3.5: Comparing Feedback Knock-down of different Parameterizations
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3.3.4 Drug inhibition of cGAS activity is recapitulated in simulation
We examined the model’s capacity to predict interferon responses in scenarios where
cGAS is exposed to an inhibitory drug (Figure 3.3.6). The experimental data originally
published by Vincent et. al. [142] confirmed drug inhibition of cGAS using an interferon
luciferase reporter assay testing across a wide range of drug concentrations. The two drugs
tested (RU.365 and RU.521) all possess a small concentration range within one order of
magnitude that induce substantial changes in IFNβ production. If this jump in IFNβ pro-
duction occurs at lower drug concentrations it suggests a higher drug potency. To model
differences in drug potency, we varied the forward rate constant (kon) affecting drug and
cGAS binding while simultaneously constraining to the experimentally determined Kd val-
ues. One of the three drugs did not have a reported Kd value and was excluded in this
analysis. The optimized rate constant for RU.365 (kon = 2.314 × 10−4 nM−1hr−1) and
RU.521 (kon = 3.099 × 10−3 nM−1hr−1) indicate that RU.521 shows the highest potency.
The reported IC50 values for each drug follow an inverse trend compared to determined
rate constants which is consistent as more potent drugs have lower IC50 values. The IC50
values calculated directly from the model simulations (displayed on Figure 3.3.5b) are in
good agreement with the experimentally determined values, with absolute errors of 0.57 μM
(RU.365), and 0.16 μM (RU.521).
(a) Mechanism
(b) Dose response curves
Figure 3.3.6: Simulated Drug Inhibition of cGAS
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3.4 Summary
Here, a first principles mathematical model of the cGAS pathway was developed and
used to evaluate emergent systems-level properties associated with interferon regulation. The
importance of the cGAS pathway is demonstrated in the growing number of pathogens and
diseases it is associated with including bacteria [101, 107], DNA viruses [108], retroviruses
[143], autoimmunity [109], cancer [29], and aging [32]. There are no existing ODE models
for this system, allowing this model to fill a gap in the field’s knowledge of cGAS pathway
dynamics. In total, working towards a quantitative, systems level understanding of the cGAS
pathway can improve insight into interferon regulation and support treatment design.
The data used to inform the model were collected from 10 experimental observations and
utilized two different categories of cells: immune cells derived from monocytes and connective
tissue cells (Table 1). Both types of cells produce an interferon response through the cGAS
pathway, but the magnitude of these responses can vary across cell type with immune cells
like plasmacytoid dendritic cells (pDCs) producing more potent responses [144]. Because of
this we restricted our data search to cell types whose responses were similar in magnitude.
Chessler [139] makes an excellent comparison showing how T. cruzi induces IFNβ expression
through the IRF3 transcription factor in both fibroblast (MEF) and macrophage (BMDM).
Both cell types produce a 1100-fold change in IFNβ mRNA expression, suggesting our use
of these cell types is justifiable. Because we use data from different sources, normalization
was performed to equally compare relative responses across the distinct experiments. This
ensured the use of different controls within experiments did not influence the model outcome.
In addition to differences in magnitude, some cell types are going to respond more rapidly to
pathway stimulation [145]. However, the data selected (shown in Figure 3.3.2) comes from
cell types which demonstrated similar IFNβ dynamics.
MCMC optimization resulted in two distinct parameterizations determined by three in-
dependent runs of the algorithm (Appendix Figure A.2.10 demonstrates the two clusters
formed). While these parameterizations all equally minimize the objective function, their
emergent behavior is different. The parameterization resulting from run 2 demonstrates be-
havior that, from a biological standpoint, seems improbable as cytosolic DNA is completely
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consumed within 1 hour. The dynamics of cytosolic DNA from run 2 parameter sets exhib-
ited no delay between cGAS binding and TREX1 degradation. A time delay should exist
because TREX1 is only produced after the cGAS and JAK/STAT pathways are activated.
The overall structuring of the ODE model required several simplifying assumptions to
reduce the size of the parameter space and remove nonlinearities, making the optimization
more tractable. One major assumption made was neglecting the dimerization of transcrip-
tion factors like IRF3. The implications of this assumption were tested, and the resulting
dynamics were compared (Appendix Figure A.2.11). The only moderate difference between
the two models was that more IRF3 was needed to create the activated dimer—leading to
a larger drop in IRF3 levels. Because we have limited knowledge of the absolute dynamics
of the IRF3 dimerization, and the relative timing of the dynamics are similar, we found this
assumption to be reasonable.
Based on calculated correlation values between the optimized parameters, we conclude
the model is suspect to issues with structural non-identifiability. The ability to explicitly
determine which parameters fall under this category is possible with small linear differen-
tial equation models, but by increasing the number the states and introducing non-linear
terms (like Michaelis Menten) the task become intractable or even impossible [146]. Having
structural non-identifiability means there exist no unique parameter set that best explains
the data. Knowing this ubiquitous problem exists in systems biology we used a Bayesian
optimization approach to consider families of parameter sets as opposed to one non-unique
parameterization. Our focus was not on the individual parameter values, but rather what
emergent properties where obtainable across all parametrizations.
The local sensitivity analysis revealed that only 3 states are strongly sensitive to param-
eter fluctuations (see Appendix Figures A.2.9 and A.2.12) and, as with observations made in
other biological pathways [147], the ranking of their sensitivity across parameters is indepen-
dent of selected parameter set. Sensitivity can guide model refinement and drug targeting,
but large uncertainties associated with biological parameters can lead to changing system
priorities. We show here that for exceptionally large distributions of parameter values, the
ranking of parameter sensitivities is constant; suggesting that sensitivity is the result of the
system architecture and not the system parameterization. Supported by this result, the sen-
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sitivity analysis suggests that IFNβ is best regulated by manipulating local mechanisms but
is still sensitive to several up and downstream kinetics. Thus, there exists multiple methods
to manipulate IFNβ concentrations and the models can be used to optimize the proposed
manipulation.
The TREX1 regulated DNA degradation appears to be critical to capturing robust in-
terferon signaling. Robustness is an emergent systems property in which a system maintains
function (i.e. interferon production) despite large changes in the intracellular environment
[117]. As shown in Figure 3.3.5, the presence of the TREX1 feedback is required to de-
grade cytosolic DNA and ultimately prevent further interferon production. Yet, if TREX1
feedback is present, large changes in parameters associated with the protein’s activity do
not strongly impact interferon production. Even a 75% reduction in TREX1 activity did
not appreciably alter IFNβ/IFNβ mRNA levels, meaning the pathway’s activity is highly
robust against perturbation in TREX1 feedback. This is important for two reasons: First,
it suggests that parameterization does not need to be highly accurate. The model can have
relatively large errors in TREX1 associated parameters and still maintain the appropriate
dynamic responses (as dictated by the simulation in Figure 3.3.2). And second, this suggests
a relatively simple experiment that would provide a strong evaluation of the model.
To show how the mode could replicate experimental measurements performed, we demon-
strated its ability to simulate drug inhibition of cGAS. The methods used to simulate
this inhibition required several assumptions including: (1) reversible drug binding to the
cGAS:DNA complex, (2) first order mass action kinetics, (3) no degradation of drug within
the cell, and (4) no interaction between the drug and unbounded cGAS (i.e. no DNA bound).
Even with these strong assumptions we were able to successfully recapitulate IFNβ dynamics
and determine IC50 values with a maximum absolute error of 0.57 μM. With more sophisti-
cated dynamics, such as the implementation of hill kinetics, drug inhibition of cGAS could
be more accurately simulated.
One assumption we did not make while adding the drug interaction into the model was
fast equilibration between the drug and cGAS complex. The timescales for DNA or drug
binding to cGAS are significantly smaller than transcription and translation events in the
model. This can be observed in the steep initial drop-off of cGAS concentration in Figure
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2. Using this assumption would be beneficial in analyzing dynamics on long timescales
as it simplifies computational complexity but were not included to allow for the potential
investigation of small timescale dynamics.
The flexibility of an ODE model provides a fast and effective method to understand how
a biological pathway behaves under diverse situations. The model presented in this paper
illustrates the dynamics of the cGAS pathway expected from a DNA transfection experiment
with and without cGAS inhibition. This is fundamentally different from in-vivo activation of
the cGAS pathway because it ignores dynamics caused by disease interactions. Many virus
strains have evolved to transcribe proteins that target the cGAS pathway [103, 106] and
cancer cells have developed mutations to evade the cGAS immune response [28]. The ODE
model presented in this paper can be easily modified and extended to predict dynamics
specific to these scenarios. Viral proteins, for example, can be included to simulate the
effective inhibition of the cGAS pathway. With these additions further hypotheses can be
tested to determine if new treatments restore the immune response. Overall predictions
garnered by the ODE model will provide crucial insight into how we can manipulate disease
outcome.
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4.0 Agent-Based Modeling Reveals Benefits of Heterogeneous and Stochastic
Cell Populations during cGAS-Mediated IFNβ Production
4.1 Introduction
The advancement of microscopy and single cell analyses have identified IFNβ expres-
sion—a critical component of the innate immune response—as an inherently stochastic pro-
cess that is regulated by interacting, highly heterogeneous cells [148, 145, 37]; however, what
advantages stochastic responses and heterogeneous populations may give to signaling in the
context of immunity remains an open topic of study. When a cell population encounters
a pathogenic threat, a majority of the population will not respond despite being infected,
and those that do will vary greatly in their response [148, 149, 150]. Multiple mechanisms
have been proposed to explain these observations, with many citing either intrinsic or ex-
trinsic sources [145, 151]. Low protein and mRNA concentrations are common intrinsic
sources of stochasticity because they result in probabilistic responses within the cell (e.g.
transcriptional busting) [152, 153, 149]. This source of noise can amplify and propagate
down signaling pathways eventually affecting gene expression and cellular behavior [154]. In
contrast, extrinsic sources implicate heterogeneity in the immune stimulus as well as spatial
variation in signaling molecules [155]. Taken together, these layers of noise and variability
coalesce to explain the complex dynamics observed in immune cell signaling.
The benefits that stochastic and heterogeneous cell populations bring to innate immune
signaling remain unclear. Some evidence suggests that cells are attempting to optimize the
potent innate immune response to simultaneously minimize pathogenic loads and maximize
cell survival [37]. Overexpressing innate immune cytokines can provoke unnecessary dam-
age to the host [156], leading to cytokine storms and chronic inflammation [157]. More
recent evidence suggests that stochasticity allows a cell population to subdivide, where some
cells produce substantial immune responses that risk apoptosis while others are preserved to
maintain tissue viability [158, 159, 153]. In contrast, hypotheses elucidating the advantages
of cellular heterogeneity are less developed. One potential explanation is bet-hedging [160],
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where less-fit individuals are maintained as a precaution to drastic changes in the environ-
ment. Others suggest that heterogeneity acts as an additional layer of non-genetic variability
[161, 162] which can impede pathogenic threats susceptible to noise [163]. Investigating why
cell populations employ stochasticity and heterogeneity during the IFNβ immune response
allows for the improvement of existing drug therapies [164] and more broadly an increased
understanding of host immune regulation.
Multiscale computational modeling can assess how cell stochasticity and heterogeneity
impact innate immune signaling across intracellular and cell population scales. However,
developing models that incorporate these features are difficult to implement because they
are conventionally modeled using separate approaches. Intracellular signaling is typically
modeled using ordinary differential equations (ODEs) by assuming spatial differences are
negligible within the cell [85, 38]. In comparison, intercellular signaling relies on diffusion
gradients described by partial differential equations (PDEs) which need to be accounted for
to model cytokine signal propagation. Combining these two modeling paradigms can of-
ten lead to stiff systems that become numerically unstable [165]. Fortunately, agent-based
modeling (ABM) methods and computational power have greatly advanced, supporting sim-
ulation of hybrid ODE, PDE, and rule-based models that easily incorporate cellular behavior
like stochasticity and heterogeneity [166, 167]. ABM is a general computational technique
that defines individual entities—or agents—containing rulesets which determine how these
agents interact with each other and the environment. The rules provided to a cellular agent
can be simple, such as basic conditional logic, or complicated, such as using ODEs to track
intracellular protein concentrations. The culmination of these interacting agents results in
emergent behavior not obtainable from modeling an individual cell [168, 169, 170]. ABMs
have been instrumental in revealing the emergence of metastasis [49], angiogenesis [171],
structural patterns within the heterogeneous tumor environment [50, 172], as well as simu-
lating granuloma formation in tuberculosis [173], stem cell differentiation [51], and cellular
damage in pulmonary fibrosis [174].
Here, we implement an ABM of the cGAS pathway, a critical component of the innate
immune system responsible for the detection of foreign DNA and expression of IFNβ [24].
Due to the expansive roles cGAS plays in disease detection (e.g. cancer [28], inflammation
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[110], acute kidney injury [175], HSV [108], HIV [102], MTB [101]), it is imperative to further
develop an understanding of this signaling pathway to continue improving new drug therapies
[176], cancer immunotherapies [177, 178], and vaccine adjuvants [179]. To accomplish this
task, the ABM is used to identify the immunologic advantages a cell population may have
when the individual cells are heterogeneous and subject to stochastic intracellular IFNβ
signaling. We show that cell populations containing heterogeneous protein compositions can
mount an IFNβ response that is stronger, weaker, or equal to homogeneous populations.
We also find that there exists an optimal level of stochasticity within the cGAS-induced
IFNβ response to pathogenic infection. These simulations further suggest that increasing
the fraction of cells that produce IFNβ does not lead to an increase in cell survival during
infection. In all, these simulations corroborate experimental observations and provide new
insight into how cell heterogeneity and stochasticity play a role in optimizing cGAS-mediated
IFNβ signaling.
4.2 Materials and Methods
4.2.1 Incorporating ODEs into an Agent-Based Model
The agent-based model is constructed on a 200 by 200 grid where each section represents
an epithelial cell (40,000 cells total, see Figure 4.3.1). The agents remain stationary, but
paracrine signaling dynamics allow neighboring cells to transmit information about their
current state and influence the population as a whole. Grid sections are sized such that the
side length is roughly equivalent to the diameter of a mammalian human cell (32 μm), which
provides the proper scale for diffusion [61, 62]. An ordinary differential equation model of
the cGAS pathway is utilized as a ruleset for each cell in the simulation [55]. This allows an
agent to detect immune stimulatory DNA (ISD) or a DNA-encoded virus and respond by
upregulating interferon beta (IFNβ). This signaling protein could then diffuse across the cell
population and upregulate the JAK/STAT pathway to promote various feedback mechanisms
including IRF7, SOCS1/SOCS2, and TREX1. The ODE model remained largely unchanged,
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except for the addition of the diffusion term on IFNβ:
∂[IFNβ]
∂t
=
kcat7[IFNβmRNA][DNA]
Km7 + IFNβmRNA
− τ7[IFNβ] +D∇2[IFNβ] (4.1)
Parameters used to simulate the model are taken from the best (i.e. lowest error) MCMC
iteration from the original ODE model. Two independent sources were found for the diffusion
coefficient of IFNβ (95 µm2/s [180] [63] and 100 µm2/s [181]) so an average of the two are
used in the simulation.
4.2.2 Agent Based Model Simulation
The ABM is simulated using the DifferentialEquations.jl package in Julia using a semi-
discretized approach [54]. The Laplacian modeling the diffusion process is discretized using a
second order central differencing scheme with no flux (Neumann) boundary conditions. This
combined with the 13 ODEs encoded in each simulated cell, results in a system of 520,000 or-
dinary differential equations. The scale of this model requires a well-optimized solver that is
efficient in both computing time and memory, as well as being numerically stable. We found
that higher order stabilized Runge-Kutta methods (e.g. ESERK5 and ROCK4 [182, 183])
were proficient in some model iterations but led to numerically unstable oscillatory states
when simulating viral infections. This is in part caused by jump discontinuities exhibited
by some of the species, such as a spike in viral DNA concentration after a cell transitions
from a healthy to infected state. We settled on using an implicit ODE solver (backward
differentiation formula, BDF [53]) which eliminates numerical instability but requires solv-
ing a computationally expensive system of linear equations at each time step. Instead of
solving the linear system directly, we use a generalized minimal residual method (GMRES)
to accelerate the BDF solver. GMRES can efficiently estimate the solution to the linear
system after a few iterations of the algorithm which helps minimizes the computational cost
of the model [184].
Two initial conditions are implemented into the model depending on whether an ISD
transfection or viral infection was simulated (Figure 4.3.2). The ISD initial condition defines
a circular region to specify a boundary between transfected and healthy cells. Cells within
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the boundary are considered infected and are given a nonzero concentration of ISD. The
viral infection initial condition uses a different approach that assumes each cell within the
population has some probability of being initially infected according to a Poisson distribution:
P (n) =
(MOI)n · e−MOI
n!
, (4.2)
here, n refers to the number of times a cell is infected, and MOI is the multiplicity of
infection. The fraction of cells initially infected are varied by changing MOI. A low dose
simulated infection, for example, would have an MOI of 10−3, which corresponds to an
average of 40 cells being initially infected at least once.
4.2.3 Simulating Cellular Heterogeneity and Stochasticity
Two methods are used to simulate differences within individual cells: heterogeneity is
modeled by changing initial conditions and stochasticity is simulated by randomly modi-
fying ODE parameters associated with IFNβ production. Initial conditions are varied by
sampling from a truncated normal distribution (bounds 0 to infinity) with a mean specified
by the original initial condition and a set variance. By surveying different variances, we can
determine how sensitive the interferon response is to heterogeneity in cellular composition.
The default variance was set to 0.5 nM2. To simulate stochastic IFNβ signaling, cells are
randomly assigned different kcat7 parametrizations (Eq. 4.1) This parameter is responsible
for IFNβ mRNA translation and is treated as a Bernoulli distributed random variable with
the probability of failure equal to the desired percentage of interferon producing cells. If
the desired percentage of interferon producing cells was 30%, for example, there would be a
30% chance the kcat7 parameter would remain unchanged and a 70% chance the parameter
value would be set to zero, effectively preventing the cell from producing IFNβ. The default
percentage was set to 20%.
4.2.4 Simulating Viral Infection
To simulate a viral infection, an additional ODE state “Virus” is added to the ABM and
the DNA state is modified to incorporate replication.
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d[V irus]
dt
= k14f [DNA]− τ14[V irus] (4.3)
d[DNA]
dt
=k1f [cGAS][DNA] + k1r[cGASc]−
kcat2[TREX1][DNA]
Km2 + [DNA]
+
[DNA](Kmax − [DNA])
Kmax
(4.4)
When a cell becomes infected by a virus, it releases DNA into the cytosol. This is
simulated in the model as a discontinuous jump in DNA concentration subject to a uniform
distribution on the interval [0,Kmax]. The modified DNA state can now vary from cGAS
binding, TREX1 degradation, or replication specified by the carrying capacity (Kmax = 0.55
nM). As DNA accumulates in the cell, it drives the production of more virions, which can
then be used as an indication of how infectious that cell is to neighboring cells.
The probability that a healthy cell transitions into an infected cell is assumed to depend
on the surrounding cell’s viral concentrations (i.e. Moore’s neighbors). Each cell is assigned
a viral load threshold value randomly sampled from a normal distribution with a mean of 800
virions and standard deviation of 200 virions. When an infected cell’s viral concentration
exceeds its given threshold, it attempts to infect each healthy neighboring cell through a
Bernoulli trial with the probably of success defaulted to 0.5. Modifying this parameter effects
how quickly the infection spreads throughout the population, with low values effectively
halting viral spread. When a healthy cell is infected, it is assigned a nonzero concentration
of viral DNA and the infected cell is set to no longer be infectious.
In addition to a viral load threshold value, cells are also randomly assigned a length
of time they are allowed to be infected. This is also sampled from a normal distribution
with a mean 8 hours and standard deviation of 1 hour. When an infected cell surpasses
its allowed time to be infected, a callback event is triggered that modifies the cells ODE
parameters. All parameters associated with transcription and translation are set to a value
of zero. Proteins, mRNA, and other molecules then quickly degrade because the cellular
agent has no means to sustain their concentrations. This method is chosen over removing
the agent from the simulation because the ODE solver would become unstable as the number
of ODEs are changed and discontinuities are introduced.
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4.3 Results
4.3.1 Stochasticity and Heterogeneity Modulate IFNβ and Increases Cell Sur-
vival
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Figure 4.3.1: Overview of the agent-based model construction. (A) The model consists of two
layers: a bottom grid of cells and a top layer portraying the concentration of IFNβ diffusing
across the cells. The bottom grid layer is colored green according to the internal concentration of
cytosolic DNA (viral or ISD) with darker colors representing higher concentrations. Healthy cells
are colored white and dead cells are colored black. Each cell possesses an ODE model of the cGAS
and JAK/STAT signaling pathways which allow for the detection cytosolic DNA, production of
IFNβ, and upregulation of feedback mechanisms. (B) The ABM can simulate heterogeneous cell
populations by manipulating the non-zero initial conditions. Initial conditions are sampled from a
normal distribution and assigned to each cell at the beginning of the simulation. (C) Cells respond
to DNA stimulus stochastically by either producing interferon (responsive) or by producing no
interferon (unresponsive). The percentage of responsive cells are varied across simulations. (D)
Healthy cells transition into an infected state subject to the viral concentrations of neighboring
cells (Moore neighborhood). As the concentration of virus increases within an infected cell, the
probability of infecting a neighboring cell also increases. (E) Infected cells then transition into
dead cells over time with increasing probability.
68
With the development of the ABM (Figure 4.3.1), we evaluated the ability of the model
to replicate different population-level experimental results and then analyzed the effects of
stochasticity and heterogeneity on cGAS signaling, virus growth, and cell death. To compare
across the various model simulations, we choose to monitor IFNβ signaling at the cell pop-
ulation level. Figure 4.3.2 illustrates the IFNβ distribution and cell state (healthy, infected,
dead) across the cell population 10 hours after the initial ISD transfection (Figure 4.3.2A
and 4.3.2D) or DNA virus infection (Figure 4.3.2B,C and 4.3.2E,F). Several simulations
were performed under different cellular and intracellular conditions to compare outcomes
when the cells are homogeneous/deterministic versus heterogeneous/stochastic cells. During
transfection (Figure 4.3.2A and 4.3.2D), a dashed-lined boundary divides the population
into primary cells, which directly receive a DNA transfection, and secondary cells, which
receive no DNA stimulus and only respond to paracrine IFNβ signaling. Transfection sim-
ulations with homogeneous/deterministic cell populations (Figure 4.3.2A) exhibited higher
overall IFNβ production and more secondary cell activation than observed in a heteroge-
neous/stochastic cell population (Figure 4.3.2D).
Viral infection simulations exhibited a different trend in the IFNβ profiles (Figures 4.3.2B
and 4.3.2E), but the number of cells dead at hour 10 is comparable in both viral infection
simulations (Figures 4.3.2C and 4.3.2F), at approximately 2%. These results suggest that
stochasticity and heterogeneity together can significantly influence the amount of IFNβ a cell
population produces (in this case reducing IFNβ); however, this influence does not extend
directly to cell survival as it remains unchanged. Stochasticity and heterogeneity appear to
benefit the cell population by diminishing the response needed to overcome the same threat.
To further develop this hypothesis, the following sections will investigate how stochasticity
and heterogeneity affect intracellular signaling and determine how each individually impacts
the immune response.
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Figure 4.3.2: Simulating IFNβ dynamics across different cell populations. The distribution of
IFNβ at 10 hours after the addition of cytosolic DNA. Cell populations were either modeled as
deterministic and homogeneous (A-C) or stochastic and heterogeneous (D-F). Panels (A) and
(D) show cell populations transfected with immunostimulatory DNA (ISD). The quarter circular
region (dotted black line) divides the cells into two populations. Cells within the boundary were
transfected with ISD and referred to as primary cells. Cells outside this region were not transfected
and referred to as secondary cells. In panels (B) and (D), a virus infection is simulated by assigning
nonzero initial conditions of DNA according to a Poisson distribution with MOI=0.01 4.2. Panels
(C) and (F) show the same viral simulation but identify cell state (healthy, infected, or dead).
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4.3.2 Dynamics of intracellular molecules are consistent with experimental ev-
idence
We next tested the ABM to see if the model could replicate bulk intracellular signaling
from cells challenged with ISD and virus (Figure 4.3.3). During ISD transfection (Figure
4.3.3A-D and Figure 4.3.3I-L) we observe a strong IFNβ response in primary cells to the
DNA stimulus, followed by the activation of the JAK/STAT pathway to upregulate feed-
back mechanisms like IRF7 and TREX1. These dynamics are a result from fitting previous
experimental data used in the ODE model (Table 1). Secondary cells also respond to IFNβ
paracrine signaling, but to a lower degree. Viral infection simulations (Figure 4.3.3E-H and
Figure 4.3.3M-P) show an enhanced response from secondary cells, particularly from feedback
mechanisms like IRF7 (Figure 4.3.3G and 4.3.3O) and TREX1 (Figure 4.3.3H and 4.3.3P).
The variance in these responses is also increased—especially in stochastic/heterogeneous cell
populations. This variance is caused by some secondary cells having no response to infection
whereas others respond more strongly than even primary cells. Overall, this suggests that
primary cells are more important to ISD transfection and that secondary cells play a more
central role in regulating viral infections.
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Figure 4.3.3: Simulating intracellular dynamics across different cell populations. The intracellular
signaling dynamics in response to ISD transfection (A-H) and viral infection (I-L). ISD transfec-
tion was further divided into different cell populations including deterministic/homogeneous (A-D)
and stochastic/heterogeneous (E-H). Average intracellular concentrations are plotted as a function
of time and are separated into cells that are transfected/infected (primary) and those that are not
(secondary cells). The bold line represents the mean trajectory within the cell population with
error bars showing the 5th and 95th percentiles.
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To further validate the ABM, we examined the impact heterogeneity and stochasticity
had on knockdown simulations. These simulations were compared to simulating just the
ODE model under the same knockout conditions. In principle, both models should follow
the same trends when the ABM dynamics are averaged over the cell population. Figure
4.3.4A-C show how both the ODE and agent-based models’ response to knockdown of the
TREX1 negative feedback loop. TREX1 is responsible for cytosolic DNA degradation, and
the model shows a robust IFNβ response to its depletion. When TREX1 is completely
knocked-out, the ABM and ODE models all exhibit a sustained inflammatory state due to
continuous IFNβ signaling.
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Figure 4.3.4: Comparing ODE and ABM knockdowns. Simulating knock down of feedback
mechanisms in three different model types: ODE, ABM with a deterministic/homogeneous cell
population, and ABM with a stochastic/heterogeneous cell population. (A-C) depict the three
simulations were the TREX1 protein was knocked down by reducing the translation rate parameter
kcat2. The percentage indicates how reduced the parameter of the respective feedback mechanism
was with 0% representing no attenuation and 100% representing total knockout. Average cell
trajectories are plotted with the shaded regions marking one standard deviation away from the
mean. (D-F) depict the same three simulations, but with IRF7 knocked down by reducing the
k12f parameter.
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IRF7 knockdowns (Figure 4.3.4D-F) show an increase in IFNβ clearance for both models,
which is an expected outcome as this protein acts as a transcription factor for IFNβ. IRF3
is the initial transcription factor for IFNβ and is thought to be replaced by IRF7 through
a positive feedback loop. With no IRF7 further driving IFNβ transcription, protein levels
quickly drop off. Of note, the ABM simulation with a heterogeneous and stochastic cell
population still followed this trend, but the separation between the levels of knockdown
were smaller because the peak IFNβ concentration was lower. In sum, the ABM captures
population-level dynamics observed in experiments, and, unlike the previous ODE model,
supports evaluating how cell heterogeneity and stochasticity impact IFNβ signaling.
4.3.3 Cellular heterogeneity can Modulate and Enhance Interferon Production
The concentrations of mRNA and signaling proteins at the initial time of infection will
possess some level of variability across the cell population and are suspected to have an
impact on immune signaling dynamics [150]. Figure 4.3.5 shows the distribution of peak IFNβ
concentrations across the cell population that result when simulating an ISD transfection in
a deterministic/heterogeneous cell population (Figure 4.3.5A) or a stochastic/heterogeneous
cell population (Figure 4.3.5B).
To distinguish paracrine-induced IFNβ production from production in transfected cells,
the cells were divided into two groups: primary and secondary. Primary cells were categorized
as being transfected at time zero hours (i.e. had an initial nonzero DNA concentration)
whereas secondary cells were not transfected and only produced IFNβ in response to paracrine
signaling. As increasing Gaussian noise is added to the initial conditions, we observe a small
decrease in peak IFNβ produced (Figure 4.3.5A and 4.3.5B, σ2 = 0 to σ2 = 0.3) followed by a
large increase in IFNβ produced (Figure 4.3.5A and 4.3.5B, σ2 = 0.4 to σ2 = 1.0) as cellular
heterogeneity increases. This trend is more pronounced in the deterministic simulation
compared to the stochastic simulation. Secondary cells produce less interferon than their
primary counterparts across all levels of variability and model types, which indicates that
DNA is a more potent stimulus for interferon production compared to STAT activation in
this model. Overall, these simulations suggest that increasing cellular heterogeneity leads to
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aberrant levels of IFNβ production. Excessive variability will lead to high levels of interferon,
but moderate levels can lower IFNβ production independently of stochasticity.
30
40
50
60
70
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
Initial Condition Variance (σ2)
IF
N
β (
nM
) 
ISD: Deterministic (63% of Cell Infected)A
5
10
15
20
25
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
Initial Condition Variance (σ2)
ISD: Stochastic (63% of Cell Infected)B
CellState
Primary
Secondary
IF
N
β (
nM
) 
Figure 4.3.5: Effect of heterogeneity on population IFNβ levels. Initial non-zero protein concen-
trations were sampled from increasingly wider (more variable) normal distributions, as shown on
the horizontal axis. With this new initialization, the models were simulated with an ISD infection
starting with 63% primary cells. The resulting distribution of peak IFNβ concentrations were taken
and partitioned into either primary or secondary cells. The cell population was simulated with (A)
deterministic IFNβ producing cells and (B) stochastic IFNβ producing cells.
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4.3.4 Aberrant STAT activation and IFNβ Degradation did not Lead to Chronic
Inflammation within Stochastic Cell Populations
The IFNβ response from cGAS activation is typically cleared through negative feedback
regulated by SOCS1/SOCS2 proteins inhibiting STAT activation [185, 186] or by TREX1 de-
grading cytosolic DNA [110]. However, aberrant activation of the interferon response can lead
to situations where a cell population can no longer clear the protein and the immune response
persists. This chronic inflammatory state can lead to further immune dysfunction and induce
potent cytokines including programmed death-ligand 1 (PD-L1), IL-10, and d-indoleamine
2,3 deoxygenase (IDO) [187]. To investigate how heterogeneity and stochasticity impact
sustained inflammatory signaling, we ran several simulations in which parameters important
to suppressing IFNβ levels are modified across different types of cell populations (homoge-
neous/deterministic cells, heterogeneous/ deterministic, and homogeneous/stochastic). We
selected parameters that describe IFNβ degradation (τ7) and STAT activation from paracrine
signaling (kcat8) because previous work found IFNβ to be sensitive to these parameters [188].
Figure 4.3.6 summarizes these simulations by displaying average IFNβ concentrations sim-
ulated one week after the initial infection (this allows the model to reach a steady state).
Figure 4.3.6A shows how a deterministic, homogeneous cell population transitions between
successfully suppressing IFNβ to having sustained IFNβ levels as the degradation rate de-
creases and the paracrine activation rate increases. Figure 4.3.6B introduces heterogeneity
into the cell population, which increases the parameter ranges that result in non-zero IFNβ
steady states, i.e. increases the parameter space in which chronic inflammation is likely.
ABM simulations with stochastic cell populations (Figure 4.3.6C) did not result in chronic
inflammatory states across the tested parameter ranges. The largest concentrations for IFNβ
at steady state never exceeded 0.001 nM (effectively no protein). These simulations suggest
that stochasticity is an important signaling feature for limiting chronic inflammation and
that features beyond normal systems-level considerations, e.g. negative feedback, should be
explored as key regulators of inflammation.
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Figure 4.3.6: Driving simulations toward chronic inflammatory states. Each box represents an
individual simulation and is colored by the mean concentration of IFNβ at the last simulated time
point (168 hours after initial transfection). Two parameters were varied: the degradation rate con-
stant for IFNβ protein (τ7) and the rate of STAT protein activation by IFNβ (kcat8). Each parameter
was varied between half and double its original optimized value. (A) Shows simulations with de-
terministic/homogeneous cell population. (B) Simulations with a deterministic/heterogenous cell
population. (C) Simulations with a stochastic/homogeneous cell population.
4.3.5 There is an optimal level of intrinsic stochasticity to Maximize Cell Sur-
vival
Simulating how a cell population would respond to a pathogenic threat provides key in-
sight into the interplay between stochasticity and the success of the innate immune response.
We next performed simulations to assess how stochasticity and cell heterogeneity impact im-
mune success by tracking the number of healthy, infected, or dead cells remaining at 48 hours
post virus infection (Figure 4.3.7). Figure 4.3.7A and 4.3.7C show the median trajectories
and the interquartile ranges of the cell states in a homogeneous/stochastic cell population
or heterogeneous/stochastic cell population, respectively. In both cases, the percentage of
IFNβ producing capable cells is left at the default value of 20%. Both the homogeneous and
heterogeneous cell populations have the largest percentage of cells infected within the first
12 hours simulation and all infected cells transition to dead based on the how long they have
been infected (see Section 4.2).
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Figure 4.3.7: Stochasticity optimizes cell survival. Stochastic interferon expression of viral infec-
tion in homogeneous (A-B) and heterogeneous (C-D) cell populations. (A) Cells states (Healthy,
Infected, and Dead) were tracked over time in ten simulations with 20% of cells producing IFNβ
to obtain median trajectories. The shaded region shows the interquartile range across the simu-
lation. (B) Each boxplot summaries the number of accumulated dead cells for ten viral infection
simulations (at t=48 hours). The percentage of cells producing IFNβ was varied from 0% (no cells
with an IFNβ response) to 100% where all cells mounted a similar IFNβ response. (C) The process
was repeated with a heterogeneous cell population, tracing cells states with 20% of cells producing
IFNβ. (D) The percentage of IFNβ producing cells was then again varied and the change in the
percentage dead cells was observed.
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A successful and optimal host immune response would minimize the number of cell deaths
and the amount of IFNβ needed to quench cytosolic DNA, as high levels would likely induce
long-term inflammation. With this measure of success defined for the immune response,
we evaluated how the cell population responded to changing the number of cells capable of
producing an interferon response. This was accomplished by randomly assigning the kcat7
parameter (Eq. 4.1) a value of zero based on the desired percentage of IFNβ producing cells
(e.g. no IFNβ producing cells would imply that all kcat7 parameters were set to zero). Figure
4.3.7B shows how the viral infection simulation was affected by the percentage of IFNβ
producing cells in a homogeneous population. When fewer cells are capable of responding
to the virus, more cells die. However, there is a wide range (40-100%) where the interferon
response has been modulated but the cell survival rate is not significantly affected. A range
of 20-30% appears to be the optimal percentage of IFNβ producing cells because it both
minimizes the number of cells lost to the infection and the energy needed to bolster an
effective immune response. Figure 4.3.7D repeats these simulations, but with a heterogeneous
cell population. There were no apparent differences found between the heterogeneous and
homogeneous cell populations, indicating the stochastic responses were primarily responsible
for the observed trends in cell survival.
4.4 Summary
The ABM method presented in this work was specifically tailored to assess how cellu-
lar heterogeneity and stochasticity impact immune signaling. Computational modeling and
systems approaches have been used to provide systems-level insight into the regulation of
immune signaling systems, however, how cellular heterogeneity and stochastic influence ro-
bust, optimal and reliable signaling is an under considered area. Using a customized ABM
that is predicated on an experimentally validated ODE model, we performed in-silico ex-
periments to determine how cellular heterogeneity and stochasticity impact overall IFNβ
production and cell death experienced during the infection. Figure 4.3.5 exemplifies how cell
heterogeneity acts as a tuning variable to regulate intracellular immunity. Low heterogeneity
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(i.e. small variations in cellular composition) allows a cell population to attain similar IFNβ
concentrations without having every cell fully respond. Lowly expressing cells can rely on
paracrine IFNβ signaling and not expend the resources necessary to maintain a cellular com-
position capable of producing a comparable response. Highly heterogeneous cell populations
magnify this behavior of having only a few cells produce an excessive amount of IFNβ that
overcompensate for the population. By tuning cellular heterogeneity, a cell population can
modulate IFNβ response potency without the need for additional cell signaling architecture.
Stochasticity, in comparison, plays an important role in maintaining cell survival. Exper-
imental evidence shows that the IFNβ response is stochastic in nature and results in at most
20% of cells responding to infection [37]. The agent-based model simulates the end result of
this stochastic behavior by varying the number of IFNβ producing cells (Figure 4.3.7). We
observed that having too few IFNβ producing cells lead to excessive cell death but increasing
the fraction of responding cells did not result in improving overall cell survival. We found
having 20-30% of cells producing interferon was an ideal balance between these two extremes.
The modeled ideal percentage of responding cells does not exactly match Zhao et. al. in
Figure 4.3.7, but other experimental studies suggest that this ideal response is virus specific
[188]. The ABM virus parameters could easily be modified to fit any viral specific IFNβ
response, but more importantly our model provides an explanation for these experimental
observations.
Past research in our group explored the incorporation of differential equations into agent-
based models using existing software. The user-friendly software NetLogo [52] was first
chosen to create an agent-based model of the cGAS pathway with the aim of elucidating
the effects of cell-to-cell interactions through paracrine signaling. A reoccurring issue that
spanned multiple softwares was the difficulty in incorporating ODE models into the ABM.
Following the demo kinetics model in NetLogo, the package allowed for simple kinetics to be
added but proved to be challenging for complex differential equations. Additionally, we did
not find any established packages to link NetLogo with more general scientific computing
languages like Matlab. Coding languages like Matlab were also tested as a platform for ABM
simulation but the ODE solvers (e.g. ode15s) were unsuccessful at solving the large systems
we desired. For this project, Julia allowed for the incorporation of ordinary differential
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equations into an ABM, as well as more control over the ODE solvers needed to simulate
the large, stiff system of equations. [189].
Critical tradeoffs were made when developing this ABM, most notably was the number
and complexity of the agents. The model assumes cells are static entities on a uniform
grid, which works when modeling epithelial cells. Modeling other cell types, conversely, may
require agents to possess attributes like shape, movement, and cellular division. These can
be more readily implemented in other ABM software like Compucell3D and Morpheus at
the cost of reducing agent count [190, 191].
Overall, this paper develops a straightforward method to translate a signaling pathway
ODE model into a hybridized agent-based model capable of handling large scale simulations.
Common signaling mechanisms like autocrine and paracrine signaling can easily be incor-
porated into the model as well as additional heterogeneous and stochastic properties that
cannot be modelled with ODEs directly. In this example of the cGAS pathway, we were able
to take experimental observations like heterogeneity cellular composition and stochasticity
in IFNβ expression and show why they would be beneficial to a cell population. With the
advent of measuring single cell dynamics in an accurate and precise manner, this modeling
framework has the potential to allow researchers to rapidly restructure other ODE models
to help explain new observations made at the single cell level.
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5.0 Conclusions
The goal of this dissertation was to (1) use systems biology methodologies—like ODE
modeling—to examine the regulation of the innate immune system and (2) extend those
methods to simulate heterogeneous cell populations across multiple length scales. Two com-
ponents of the innate immune systems were investigated: metabolic reprogramming during
sepsis and interferon beta expression induced by cGAS DNA detection. Both of these im-
mune signaling events are relevant to a number of diseases/conditions (e.g. acute kidney
injury [175, 68], viral infection [108, 102], cancer [112, 113, 28]), so building dynamic models
to describe their progression is key to developing new pharmaceuticals and improving patient
outcome.
5.1 Metabolic Reprogramming
With metabolic reprogramming during sepsis (Aim 1), there was preliminary evidence
that tubular epithelial cells (TECs) in the kidney transitioned between normal metabolism
(oxidative phosphorylation) in the mitochondria and aerobic glycolysis [11]. This metabolic
shift is hypothesized to occur because cells are entering either a resistive or tolerant state
to a perceived pathogenic threat. Aerobic glycolysis is triggered early on during infection
driving TECs into a more resistive state. If cells remain in this state for a prolonged period
of time or fail to transition back to more tolerant oxidative phosphorylation, organ damage
like fibrosis can occur, resulting in chronic kidney disease (CKD).
The goal of this first aim was to develop a model of the pathways regulating metabolism
in TECs. This involved crosstalk between the AMPK, TLR4/Akt/mTOR, and HIF-1 path-
ways which controlled oxidative phosphorylation, LPS detection, and glycolytic pathways
respectively. With the implementation of such a model, metabolic shifting between OX-
PHOS and aerobic glycolysis could be simulated. The benefit of this model development
is the ability determine what components of the signaling pathways are most sensitive to
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promoting metabolic reprogramming. Global sensitivity analysis (GSA) identified AMPK
phosphorylation to be highly insensitive to changes in metabolic state (shifting to glycoly-
sis). In other words, small variations in AMP/ATP ratios caused by metabolic shift were
compounded with insensitive parameters leading to minimal downregulation in OXPHOS.
This model for simulating metabolic reprogramming in sepsis had some notable limita-
tions. One is that the model focused more on building an understanding of the regulators
controlling the two metabolic pathways and was less concerned with simulating dynamics
within those metabolic pathways. Effectively, OXHPOS and Glycolysis are lumped into
individual terms. This was done because limited kinetic data was available to model the
complexities of say the entire electron transport chain. This more minimalist approach is
similar to more extreme example of not modeling every quantum mechanical interaction of
a box sliding down a ramp. While both of these modeling schemes would be more realistic,
they can lead to simulations that are intractable even on modern hardware and difficult to
draw conclusions from. The modeler needs to strike a balance between biological detail and
model interpretability. That being said, one future direction to improve this model would
be the addition of kinetically informed regulations like SIRT1, which is controlled by AMPK
and regulates biogenesis of mitochondria through PGC1-α.
A more ambitious direction for this project would be to expand the ODE simulation
into a multiscale ABM simulation. This simulation could vary the number of tolerant and
resistant cells to determine its impact on acute kidney injury. Additionally, intercellular
signaling between TECs and immune cell signaling could be incorporated to develop a more
holistic view of the kidney nephron during sepsis.
5.2 Computation Model for the cGAS Pathway
The second aim was focused on model development for the recently discovered cytosolic
DNA sensor cGAS. RNA sensors like the RIG-I had been well established at the time [19],
but it was not until 2013 that cGAS was identified as the putative DNA sensor [24]. The
detection of aberrant DNA in the cytosol is a precursor for several dangerous events including
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pathogenic invasion, cancer [29], autoimmune disease [110, 30], and senescence [192, 32].
By developing a computational model of this DNA detection mechanism, we were able to
investigate hypotheses explaining dynamic regulation and show emergent system properties
in silico.
The cGAS model consisted of the titular enzyme, activation of the interferon beta re-
sponse, and downstream regulators expressed through the JAK/STAT pathway. This in-
cluded negative feedback loops such as TREX1 degrading cytosolic DNA and positive feed-
back loops like IRF7 taking over as the primary interferon transcription factor. The model
was fit to experimental data using a Bayesian approach (Markov Chain Monte Carlo) which
provides significant advantages over traditional parameter fitting. Chief among these are the
ability to escape local minimum solutions that gradient descent algorithms fall victim to. If
the MCMC algorithm successfully samples the parameter space, distributions for parame-
ter values are obtained which provide additional information about parameter sensitivity. A
broad, flat distributions, for example, indicates that parameter can vary greatly with without
impacting the overall model fit.
One of the main results of the cGAS ODE model was the prediction of robustness in
TREX1 signaling. TREX1 is exonuclease upregulated by a type I interferon response whose
function is to degrade double stranded DNA that accumulates in the cytosol. The model in
Aim 2 showed that knocking down TREX1 activity had a limited effect on IFNβ signaling
and that only complete knockout of TREX1 activity lead to a sustained IFNβ producing
state (Figure 3.3.5a). This prediction still needs to be experimentally validated, but looking
at previously published studies seems to corroborate this claim. Zhang et.al., for example,
was investigating the role of cGAS dependent IFNβ expression in Chlamydia trachomatis in-
fection [193]. In this study, both TREX1 knockouts and siRNA knockdowns were performed
to determine the resulting IFNβ mRNA fold change. When polydA:dT (a synthetic DNA
immunostimulant) was used as a transfecting agent, the difference in IFNβ mRNA expres-
sion for the knockdown was small (control: ∼7 fold, TREX1 KD: ∼11 fold) whereas the
difference from the total knockout was large (control: ∼10,000 fold, TREX1 KO: ∼88,000
fold). This does suggest some signaling robustness, but further experimentation would have
to be done. These knockout and knockdown measurements were only performed at one time
84
point and there are no measurements to determine if this IFNβ response if sustained in the
cell population. This could be accomplished, for example, by using an shRNA knockdown
cell line coupled with a fluorescent reporter for IFNβ mRNA.
5.3 Multi-Scale Agent-Based Modeling
Aim 3 was driven by two key observations exhibited by the interferon response in cells.
The first was the apparent failure of some cell in a population to respond to an immunos-
timulant (whether that be a virus or DNA fragment). The percentage varies depending on
context, but up to 85% of stimulated cells will mount no immune response [37, 188]. The
model discussed in Aim 2 cannot predict this stochastic observation because ODEs are com-
pletely deterministic given an initial condition. If there was cGAS stimulus, the ODE model
would always predict an accompanying IFNβ upregulation because this portion of cGAS
signaling pathway contains no negative feedback regulation.
The second observation was that the magnitude of interferon produced by cells varied
greatly despite be given identical treatments [145, 148]. This was further confirmed when
Rand et. al. examined “sister” cells (cells that had just divided) and showed that the
correlation between pairs of IFNβ expressing cells was very weak (r2 = 0.11) [145]. The ODE
model in Aim 2 could not predict this phenomenon in a single execution of the simulation.
To model this observation, the ODE model would have to be simulated multiple times while
varying the initial conditions (each simulation would then represent a different cell in the
population). This works to an extent, but assumes that (1) heterogeneity is caused by
differences in intracellular protein concentrations and (2) negligible intercellular signaling.
The main goal of Aim 3 was to build a model that could emulate these observations and
explain what benefit—if any—they brought to a cell population. This question is important
because it impacts how we modify immune response. If we attempt and stimulate the inter-
feron response by artificially increasing the number of expressing cells, essential regulatory
signals that control IFNβ could be disrupted. Excessive tissue damage and organ failure can
result from an overactive immune response, as demonstrated in failed IFNβ treatments [194].
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To explain these two observations, a new modeling scheme needed to be developed.
The ODE cGAS model was already established so it was sensible to try and extend this
model as opposed to implementing something entirely new. Extending the model was also
advantageous because the process could be generalized to extend other ODE based models
like the sepsis model in Aim 1. The resulting model that incorporated both heterogeneity
and stochasticity can be best described as a hybrid ODE/PDE/ABM model which benefits
from each of the individual modeling types. The ODE system was used to track intracellular
concentrations as before, PDEs were used to simulate diffusion across the cell population,
and the ABM allowed these previously deterministic models to react to probabilistic events.
The main finding of this aim was the benefit stochasticity provided to a cell population.
Simulated cell populations with a reduced number of IFNβ expressing cells experienced a sim-
ilar number of cell deaths when compared to fully expressing cell populations (Figure 4.3.7).
This benefits the cell population in a number of ways. First, mounting an immune response
is energy intensive, so only needing some responding cells reduces this burden. Second, the
immune response is more challenging to predict, making is more difficult for a pathogenic
threat to adapt. And last, by minimizing the interferon producing cells, the risk of overstim-
ulating the immune response and causing tissue damage is reduced.
A future direction for this type of hybrid agent-based modeling scheme would be to re-
place ODEs with stochastic differential equations (SDEs). With ordinary differential equa-
tions, the parameters are usually considered constant. The entire objective of parameter
fitting is to determine these constants to make inferences about the ODE model. SDEs
break this assumption and allow parameters to be defined as random variables. The result
is a system that follows the governing equations used to build the ODE system but can
randomly fluctuate away the determined trajectory. Running an SDE will give a different
trajectory each time, but the average trajectory will converge to the ODE solution (given
small noise limits). This consideration for signal noise can have a substantial effect on a
cell population, depending on the extent of noise introduced. Some cells could produce
massive IFNβ responses while others could very well produce no detectable signal. Steady
states could bifurcate leading to subpopulations of cells responding differently to the same
signal. This would be difficult to model using the current hybrid approach as callback rules
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for changing parameter values would need to be added which would substantially reduce
computational efficiency.
The switch between to SDEs would be straightforward using DifferentialEquations.jl be-
cause it provides a large library of solvers tailored to different classes of SDEs. One would
simply have to define a noise matrix and choose an appropriate solver. Numerical algorithms
to solve for SDEs is still a developing field, which means the number of cells simulated in Aim
3 would likely need to be reduced as many of the available ODE solvers were unsuccessful
at solving this system. Additionally, the system would have to be simulated multiple times
to get average trajectories which would be feasible, but computationally expensive.
Figure 5.3.1: Preliminary SDE Simulation. Each of the 400 time series represents a cell Sting
protein concentration dynamically responding to an ISD stimulation. A small, constant noise term
was added to each species in the ABM model and simulated using the SOSRI solver. Some cells
are initially transfected with DNA, decreasing their inactive Sting levels while other cells randomly
fluctuate at steady due to added noise. Transfected cells can be observed bifurcating, leading to
two steady states for Sting.
Overall, these studies were successful in revealing insights into the innate immune system
that were difficult to ascertain with traditional biological methods. It puts emphasis on the
fact that the innate immunity is a dynamic, complex, and nonlinear system that demands
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advanced computational techniques to even begin to understand its intricacies. Intensive
collaboration between immunologist and engineers needs to be brought to the forefront of
this field because neither discipline can fully decode cell signaling regulation individually.
Progress is being made toward the collection of genome wide, live, single cell measurements
which will provide invaluable information for computational modeling; but until such data
become ubiquitous, systems biology modeling will be a highly iterative, trial-and-error pro-
cess. The models presented in this work are no exception. New biological discoveries are
constantly changing our understanding of this system. For example, there are been recent ev-
idence that cGAS is predominately localized in nucleus and not constitutively activate in the
cytosol which would influence how the cGAS pathway is modeled. This work is a snapshot
of our current understanding of how the innate immune system detects dangerous situation,
what response a cell population takes (changing metabolism, producing cytokines), and how
that response is regulated. Ultimately, these insights into immune system dynamics will help
explain why certain treatments fail and pave the way for new, more effective therapies.
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6.0 Collaborative Projects
I have collaborated on a number of projects that are peripherally related to this main
body of work, but do not fall into the main theme of using systems biology to understand
pathogen associated molecular patterns. Here, I will summarize the purpose of these projects
and highlight any important results that were determined.
6.1 Vir-ed: An Educational Virtual Reality Application for Teaching Virology
For this project, I led and managed a team of software engineers at Full Sail University
in Florida to develop an educational virtual reality (VR) app teaching users about this
dissertation research related to cGAS. Because this software utilized VR, users were placed
in a 3D virtual cell environment they could explore and use to discover biological concepts
related to virology.
The are two campaigns the user can play through. The first follows the process of a virus
invading a cell. Users are guided through parts the viral life cycle like surface attachment and
replication using mini-games that test for biological knowledge and skill. The second flips
this perspective and discusses how the cGAS pathway is used as a cellular defense mechanism
against viral infection. The mini-games in this section focus on components of the cGAS
pathway, like how cGAMP is formed from ATP and GTP in the enzymatic pocket of cGAS
when DNA is bound. Performing well in these mini-games unlocks trophies of the different
biological components in the game (e.g. the Sting protein, DNA, etc.) which come with
detailed descriptions of their function. After completing both campaigns, users unlock an
additional survival-based game were they are tasked with maintaining a cell population and
defending them against invading viruses. They have to balance cellular defense, immunity,
and production using their knowledge of the given anti-viral interferon stimulated proteins.
To promote this project, it was presented at the STEAM Showcase hosted by Schell
Games (the largest full-service education and entertainment game development company in
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the United States), and play-tested with students at Plum Senior High School to gather
feedback and gauge interest. This project even garnered some publicity when we were
interviewed with the Pittsburgh Post-Gazette.
The free app is available on the Google play store and iOS (can also search for “Vir-ed”).
Figure 6.1.1: Screen captures of Vir-ed, the virtual reality app built to educate users about
introductory biology, virology, and the cGAS pathway. Pictured above is a virion traveling through
the circulatory system, a memory mini-game to explain nucleotide bases, a survival game to defend
cells against viral invasion, and an aiming mini-game to place ATP and GTP into DNA bound
cGAS.
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6.2 Pathogenesis of Influenza A(H7N9) Virus in Aged Nonhuman Primates
In this collaborative project I worked with Yoshihiro Kawaoka’s Lab in the Institute
of Medical Science at University of Tokyo to understand the impact of aging on influenza
A infection. Viral infections, especially influenza A, are observed to preferentially cause
higher mortality rates in the elderly, but the exact mechanism for this process is ill-defined.
To improve our understanding of this unknown mechanism, Yoshihiro’s group infected a
non-human primate model with influenza A (H7N9 strain) and measured the pathology,
immunology, and genetic variability over time.
My contribution to this project was to perform a gene functional enrichment analysis
using the collected micro-array data. This bioinformatic approach takes gene expression data
and determines a set of differentially expressed genes (up or down regulated) that contribute
to differences between groups. By determining these unique gene signatures, we can use
gene ontology to identify matching biological functions that are enriched for this differential
expressed genes associated with influenza and aging.
There were two key findings to this study, the first was the identification of IL-6 being
down-regulated in aging animals, which likely contributed to the their high pathogenicity of
influenza A(H7N9). The second finding showed that while type-1 interferon activated genes
were equally expressed in both age groups, protein levels were significantly lower in aged
animals. This dissonance between gene expression and protein production was attributed
to the association between aging and the down-regulation of protein synthesis found in
previous studies [195]. For more information related to this project, one can refer to our
recently accepted publication [196].
91
Appendix A cGAS Model
A.1 Ordinary Differential Equations
d [cGAS]
dt
= −k1f · cGAS ·DNA+ k1r · cGASc (A.1)
d [DNA]
dt
= −k1f · cGAS ·DNA+ k1r · cGASc−
kcat2 · TREX1 ·DNA
Km2 +DNA
(A.2)
d [cGAMP ]
dt
= k3f · (cGAStot − cGAS)− k4f · cGAMP · STING
+ k4r · (STINGtot − STING)− τ3 · cGAMP (A.3)
d [STING]
dt
= −k4f · cGAMP · STING+ k4r · (STINGtot − STING) (A.4)
d [IRF3]
dt
= −kcat5 · IRF3 · (STINGtot − STING)
Km5 + IRF3
+ k5r · (IRF3tot − IRF3) (A.5)
d [IFNβm]
dt
=
kcat6 · (IRF3tot − IRF3)
Km6 + (IRF3tot − IRF3)
+ k6f · IRF7Pn− τ6 · IFNβm (A.6)
d [IFNβ]
dt
=
kcat7 · IFNβm
Km7 + IFNβm
− τ7 · IFNβ (A.7)
d [STATP2n]
dt
=
kcat8 · IFNβ
Km8 + IFNβ
· 1
1 + k8f · SOCSm
− τ8 · SOCSm (A.8)
d [SOCSm]
dt
= k9f · STATP2n− τ9 · SOCSm (A.9)
d [IRF7m]
dt
= k10f1 · STATp2n+ k10f2 · IRF7Pn− τ10 · IRF7m (A.10)
d [TREX1m]
dt
= k11f · STATP2n− τ11 · TREX1m (A.11)
d [IRF7Pn]
dt
= k12f · IRF7m− τ12 · IRF7Pn (A.12)
d [TREX1]
dt
= k13f · TREX1m− τ13 · TREX1 (A.13)
d [cGAS]
dt
= −k1f · cGAS ·DNA+ k1r · cGASc− kon · cGASc ·Drug + koff · cGASn (A.14)
d[Drug]
dt
= −kon · cGASc ·Drug + koff · cGASn (A.15)
d[cGASn]
dt
= kon · cGASc ·Drug − koff · cGASn (A.16)
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A.2 Parameters
Table 2: Summary of Parameters in ODE Model
Number Parameter Units Minimum Constraint Maximum Constraint log10 Value (Run 1) log10 Value (Run 2) log10 Value (Run 3)
1 k1f 1/(nM·hour) -3 1 0.429732 -0.14158 0.571135
2 k1r 1/hour -2 2 0.685785 -0.60234 0.81712
3 kcat2 1/hour 3 8 5.375736 7.916804 3.922932
4 Km2 nM 1 6 4.790203 1.236027 3.344868
5 k3f 1/hour 2 6 2.713831 2.853165 2.703932
6 k4f 1/(nM·hour) -3 1 -1.44837 -1.56758 -1.57522
7 k4r 1/hour -2 2 0.874307 0.768601 0.762453
8 kcat5 1/hour 2 6 4.348857 2.061381 4.525882
9 Km5 nM 1 5 4.050239 1.740002 4.220628
10 k5r 1/hour -2 2 -0.02962 -0.0882 -0.02824
11 kcat6 nM/hour 1 5 2.315854 2.670361 2.950268
12 Km6 nM 1 5 4.013067 4.312452 4.643317
13 k6f 1/hour -2 2 -1.55904 -1.82669 -1.53605
14 kcat7 nM/hour 4 8 7.677969 5.800111 6.377869
15 Km7 nM -3 5 0.585172 -0.9078 0.996437
16 τ7 1/hour 2 6 4.087883 3.546575 2.382462
17 kcat8 nM/hour -2 2 1.114157 1.00444 1.169599
18 Km8 nM -2 2 1.893234 1.744374 1.97878
19 k8f 1/nM -2 2 -1.68035 -2.12436 -1.60521
20 k9f 1/hour -2 2 -2.23089 -2.20471 -2.23297
21 k10f1 1/hour -2 2 -2.99886 -2.99924 -2.99893
22 k10f2 1/hour -2 2 -1.95019 -1.9481 -1.95154
23 k11f 1/hour -4 1 -2.99991 -2.99966 -2.99998
24 k12f 1/hour -2 2 1.999768 1.998867 1.999795
25 k13f 1/hour -1 4 1.180231 1.186086 1.187107
Number Parameter Units Value Reference
26 τ3 1/hour 0.96 [197]
27 τ6 1/hour 0.347 [137]
28 τ8 1/hour 1.238 [135]
29 τ9 1/hour 1.507 [137]
30 τ10 1/hour 0.347 [137]
31 τ11 1/hour 0.165 [136, 137]
32 τ12 1/hour 6.93 [198]
33 τ13 1/hour 0.0178 [135, 136]
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Figure A.2.1: Each plot gives the Gelman-Rubin diagnostic for a given parameter after each
iteration. Convergence to a value of one indicates agreement between the different MCMC runs.
94
Figure A.2.2: For each run the acceptance rate is shown for all parameters optimized.
95
Figure A.2.3: Autocorrelation within chains are tested to determine health of the MCMC runs.
Here we show the autocorrelation as a function of lag or distance between tested values for a
represented MCMC iteration (Run 1).
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Figure A.2.4: Component errors of the objective function. Here we show the errors associated
with (A) the differences between normalized model and observations and (B) differences between
expected and peck magnitudes. Each line represents the total error for all species.
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Figure A.2.5: Trace plots for all of the MCMC runs are plotted. The x-axis is the iteration of
the MCMC algorithm and the y-axis is the log-scaled value of the parameter. The limits of the
y-axis are the scaled to the constraints imposed on the parameters. All of the MCMC reiterations
are plotted (run 1 [red], run 2 [gray] and run 3 [blue]) showing how the algorithm sampled the
parameter space.
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Figure A.2.6: Histograms are given for all the optimized parameters. Each color shows one of
the three MCMC runs performed, run 1 (red), run 2 (gray), and run 3 (blue). These histograms
represent the posterior probability distributions determined by the MCMC algorithm.
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Figure A.2.7: To determine how well the parameter subsets represented the overall parameter
sets determined in MCMC we plot the summary statistics for the top 1000 parameter sets (Subset)
and the top 1 million parameter sets (All parameter sets). We show all of the comparisons across
the different MCMC runs.
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Figure A.2.8: Plotted are the Pearson’s correlation between each of the optimized parameters.
Blue represents a positive correlation whereas red represents a negative correlation. The last million
MCMC iterations are used to examine the correlations.
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Figure A.2.9: Parameter Sensitivity Analysis (All Species). Here we show another representation
of the sensitivity analysis for all of the species in the model. The mean maximum sensitivity
is plotted from the top 1000 parameter sets. Positive sensitivity is shown in red and negative
sensitivity is shown in green.
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Figure A.2.10: Parameter Clustering. Principle Component Analysis of the top 100 parameter
sets for each of the three runs. Plotted are clustered parameter sets as determined by PCA. Each
dot represents a column vectors containing the values for the 25 optimized parameters. Colors are
assigned based on the MCMC run they originate.
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Figure A.2.11: IRF3 Dimerization Assumption. The assumption of lumping dynamics describing
IRF3 formation was assessed. Two model structures were simulated: the original (lumped) and
a modified model (dimer) that considered dimerization to activate IRF3. (A) Both models were
simulated using the best parameterization found in run 1. (B) The same top 1000 parameter
ensembles (see figure 2) were simulated showing range of dynamics observed by the modified model.
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Figure A.2.12: Sensitivity Magnitudes on Parameter Perturbation. Time courses are plotted
to demonstrate how the magnitudes of different species change relative to the sensitivity of the
parameters. (A) Demonstrates responses for species to a doubling of the sensitive parameter k3f.
(B) Demonstrates responses for species to a doubling of the insensitive parameter k8f.
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Appendix B Sepsis Model
B.1 Ordinary Differential Equations
dAMP (t)
dt
=− k1af ·AMPKp− k1bf ·HIF1 + k1r (B.1)
dATP (t)
dt
=k1af ·AMPKp+ k1bf ·HIF1− k1r (B.2)
dAMPK(t)
dt
=−AMPK · k2f ·AMP +AMPKp · k2r ·ATP −AMPK · k3f · CaMKIIa (B.3)
dAMPKp(t)
dt
=AMPK · k2f ·AMP −AMPKp · k2r ·ATP +AMPK · k3f · CaMKIIa (B.4)
dCaMKII(t)
dt
=− CaMKII · k4f ·ROS + k4r · CaMKIIa (B.5)
dCaMKIIa(t)
dt
=CaMKII · k4f ·ROS − k4r · CaMKIIa (B.6)
dTSC2(t)
dt
=− TSC2 · k5f ·AMPKp+ TSC2p · k5r ·Aktp (B.7)
dTSC2p(t)
dt
=TSC2 · k5f ·AMPKp− TSC2p · k5r ·Aktp (B.8)
dRheba(t)
dt
=−Rheba · k6f · TSC2p+ k6r ·Rheb− k7f ·mTORC1 ·Rheba+ k7r ·mTORC1Rheba (B.9)
dRheb(t)
dt
=Rheba · k6f · TSC2p− k6r ·Rheb (B.10)
dmTORC1(t)
dt
=− k7f ·mTORC1 ·Rheba+ k7r ·mTORC1Rheba (B.11)
dmTORC1Rheba(t)
dt
=k7f ·mTORC1 ·Rheba− k7r ·mTORC1Rheba (B.12)
dSIRT6(t)
dt
=k8f ·AMPKp− τ8 · SIRT6 (B.13)
dHIF1a(t)
dt
=
k9f ·mTORC1Rheba
SIRT6 + 1
− τ9 ·HIF1a− k10f ·HIF1a+ k10r ·HIF1 (B.14)
dHIF1(t)
dt
=k10f ·HIF1a− k10r ·HIF1− τ11 ·HIF1 (B.15)
dLPS(t)
dt
=− k12f · LPS · TLR4 + k12r · TLR4LPS (B.16)
dTLR4(t)
dt
=− k12f · LPS · TLR4 + k12r · TLR4LPS (B.17)
dTLR4LPS(t)
dt
=k12f · LPS · TLR4− k12r · TLR4LPS (B.18)
dPI3K(t)
dt
=− PI3K · k13f · TLR4LPS + k13r · PI3Ka (B.19)
dPI3Ka(t)
dt
=PI3K · k13f · TLR4LPS − k13r · PI3Ka (B.20)
dAkt(t)
dt
=−Akt · k14f · PI3Ka+ k14r ·Aktp (B.21)
dAktp(t)
dt
=Akt · k14f · PI3Ka− k14r ·Aktp (B.22)
dROS(t)
dt
=k15f ·AMPKp− τ15 ·ROS (B.23)
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Appendix C ABM Code
C.1 ProblemGenerator.jl
C.1.1 Import Dependencies
#Import Packages needed for simulation
using DifferentialEquations, Sundials #For implementing Differential equations
using LinearAlgebra, SparseArrays, Distributions, Statistics, Random #Linear Algebra and Statistics
using CSV, DataFrames #Data handling
using StatsPlots #For graphing
using JLD2, FileIO #Saving simulations
C.1.2 Define all the constants that will not change
#Constants for all cells
const N=200 #number of grid points along one dimensions
const nCells = N^2 #number of cells in the simulation
const cellVol = 3e-12 #Cell Volume (liters)
const Na = 6.02e23 #Avagadro's number
const species = 14 #Number of states within each cell (including virus)
const moi = 1.0e-2 #Multicity of infection
const cellIndicies = CartesianIndices(zeros(N,N)) #set of indices for looping through every cell
#Function that converts molecules to nM
m2c(molecule) = @. 1e9*molecule/(cellVol*Na)
#Constants for all simulations
const tspan = (0.0,48.0) #Time span for simulation
const ΔIFNβ = zeros(N,N) #Define memory space to hold the Laplacian
const statesNames = ["cGAS","DNA","Sting","cGAMP","IRF3","IFNbm","IFNb","STAT",
"SOCSm","IRF7m","TREX1m","IRF7","TREX1","Virus"] #for plotting
const θNames = [:k1f, :k1r, :k3f, :k3r, :k4f, :kcat5, :Km5, :k5r, :kcat6, :Km6, :kcat7,
:Km7, :kcat8, :Km8, :k8f, :k9f, :k10f1, :k10f2, :k11f, :k12f, :k13f, :k6f, :kcat2,
:Km2, :τ4, :τ6, :τ7, :τ8, :τ9, :τ10, :τ11, :τ12, :τ13, :k14f,:τ14] #Parameter names
#These species are not starting at zero
const nonZeroSpeciesIdx = [1,3,5] #cGAS, Sting, IRF3
const nonZeroSpeciesValues = m2c([1e3, 1e3, 1e4]) #convert to concentration
#This function modifies initial values by adding guassian noise
#Standard deviation is same magnitude as mean
# If p=0.5 then: (u1=0.1 u2=100) (sigma1=0.05 sigma2=50) instead of (sigma1=0.5 sigma2=0.5)
AddNoise2States(p) = [truncated(Normal(μ,p*μ),0,Inf) for μ in nonZeroSpeciesValues]
#Often it is useful to pass parameters between functions during the ODE solve,
#This struct hold all the parameters that we need to keep track of
mutable struct ParContainer{T}
par::T #Rate Constants
mass::Vector{Array{Float64,2}} #Mass balances
deathParameter::Array{Float64,2} # 0 or 1 indicating cell is dead
DNAReplicate::Int64 #0 if ISD, 1 if Virus
cellsInfected::Array{Float64,2} #Time cell was infected
cellsDead::Array{Float64,2} #Time cell was killed
infectFirstAttempt::BitArray{2} #Has cell tried to infect neighbors?
end
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C.1.3 Helper function that discretizes the Laplacian
#u is updated with Laplacian estimate from u
function (Δu,u)
#Get dimensions of the input and define some constants
n1, n2 = size(u)
Δx = 32.0 #Grid spacing (diameter of cell in μm)
D=97.5*3600.0 #Diffusion coefficient (μm^2/hr)
h = D/Δx^2
# internal nodes
for j = 2:n2-1
for i = 2:n1-1
@inbounds Δu[i,j] = h*(u[i+1,j] + u[i-1,j] + u[i,j+1] + u[i,j-1] - 4*u[i,j])
end
end
# left/right edges
for i = 2:n1-1
@inbounds Δu[i,1] = h*(u[i+1,1] + u[i-1,1] + 2*u[i,2] - 4*u[i,1])
@inbounds Δu[i,n2] = h*(u[i+1,n2] + u[i-1,n2] + 2*u[i,n2-1] - 4*u[i,n2])
end
# top/bottom edges
for j = 2:n2-1
@inbounds Δu[1,j] = h*(u[1,j+1] + u[1,j-1] + 2*u[2,j] - 4*u[1,j])
@inbounds Δu[n1,j] = h*(u[n1,j+1] + u[n1,j-1] + 2*u[n1-1,j] - 4*u[n1,j])
end
# corners
@inbounds Δu[1,1] = h*(2*(u[2,1] + u[1,2]) - 4*u[1,1])
@inbounds Δu[n1,1] = h*(2*(u[n1-1,1] + u[n1,2]) - 4*u[n1,1])
@inbounds Δu[1,n2] = h*(2*(u[2,n2] + u[1,n2-1]) - 4*u[1,n2])
@inbounds Δu[n1,n2] = h*(2*(u[n1-1,n2] + u[n1,n2-1]) - 4*u[n1,n2])
end
C.1.4 This is the ODE model for the cGAS pathway
# Define the discretized PDE as an ODE function
function Model!(du,u,p,t)
#Species
cGAS = @view u[:,:,1]
DNA = @view u[:,:,2]
Sting = @view u[:,:,3]
cGAMP = @view u[:,:,4]
IRF3 = @view u[:,:,5]
IFNβm = @view u[:,:,6]
IFNβ = @view u[:,:,7]
STAT = @view u[:,:,8]
SOCSm = @view u[:,:,9]
IRF7m = @view u[:,:,10]
TREX1m = @view u[:,:,11]
IRF7 = @view u[:,:,12]
TREX1 = @view u[:,:,13]
Virus = @view u[:,:,14]
#Derivatives
d_cGAS = @view du[:,:,1]
d_DNA = @view du[:,:,2]
d_Sting = @view du[:,:,3]
d_cGAMP = @view du[:,:,4]
d_IRF3 = @view du[:,:,5]
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d_IFNβm = @view du[:,:,6]
d_IFNβ = @view du[:,:,7]
d_STAT = @view du[:,:,8]
d_SOCSm = @view du[:,:,9]
d_IRF7m = @view du[:,:,10]
d_TREX1m = @view du[:,:,11]
d_IRF7 = @view du[:,:,12]
d_TREX1 = @view du[:,:,13]
d_Virus = @view du[:,:,14]
#Parameters
k1f, k1r, k3f, k3r, k4f, kcat5, Km5, k5r, kcat6, Km6, kcat7, Km7, kcat8, Km8, k8f, k9f, k10f1, k10f2, k11f,
k12f, k13f, k6f, kcat2, Km2, τ4, τ6, τ7, τ8, τ9, τ10, τ11, τ12, τ13, k14f, τ14 = p.par
#Constants from the mass balances
cGAStot, Stingtot, IRF3tot = p.mass
#Which cells are dead?
skull = p.deathParameter
#Should DNA be allowed to replicate (only with virus, not with ISD)
rep = p.DNAReplicate
#Calculate the diffusion of IFNβ
(ΔIFNβ,IFNβ)
#Update derivatives for each species according to model
@. d_cGAS = -k1f*cGAS*DNA + k1r*(cGAStot - cGAS)
@. d_DNA = -k1f*cGAS*DNA + k1r*(cGAStot - cGAS) - kcat2*TREX1*DNA / (Km2 + DNA) + rep*skull*DNA*(0.55-DNA)/0.55
@. d_Sting = -k3f*cGAMP*Sting + k3r*(Stingtot - Sting)
@. d_cGAMP = k4f*(cGAStot - cGAS) - k3f*cGAMP*Sting + k3f*(Stingtot - Sting) - τ4*cGAMP
@. d_IRF3 = -kcat5*IRF3*(Stingtot - Sting) / (Km5 +IRF3) + k5r*(IRF3tot - IRF3)
@. d_IFNβm = skull*kcat6*(IRF3tot - IRF3) / (Km6 + (IRF3tot - IRF3)) + skull*k6f*IRF7 - τ6*IFNβm
@. d_IFNβ = skull*kcat7*IFNβm / (Km7 + IFNβm) - τ7*IFNβ + ΔIFNβ #Add the diffusion in here
@. d_STAT = skull*kcat8*IFNβ / (Km8 + IFNβ) * 1.0/(1.0+k8f*SOCSm) - τ8*STAT
@. d_SOCSm = skull*k9f*STAT - τ9*SOCSm
@. d_IRF7m = skull*k10f1*STAT + skull*k10f2*IRF7 - τ10*IRF7m
@. d_TREX1m = skull*k11f*STAT - τ11*TREX1m
@. d_IRF7 = skull*k12f*IRF7m - τ12*IRF7
@. d_TREX1 = skull*k13f*TREX1m - τ13*TREX1
@. d_Virus = skull*k14f*DNA - τ14*Virus
end
C.1.5 Set up function that will return an ODE problem to solve
function ModelSetup(infectionMethod,IFNStoch,Hetero)
#Parameter values for the ODEs
θVals = [2.6899, 4.8505, 0.0356, 7.487, 517.4056, 22328.3852, 11226.3682,0.9341,
206.9446, 10305.461, 47639.70295,3.8474, 13.006, 78.2048, 0.0209,
0.0059, 0.001, 0.0112, 0.001, 99.9466, 15.1436,0.0276, 237539.3249,
61688.259, 0.96, 0.347, 12.2428736,1.2399, 1.5101, 0.347, 0.165, 6.9295,
0.0178]
θVirus = [1.0, 1.0] # k14f τ14 (Virus Parameters)
append!(θVals,θVirus) #Append the virus parameters to the orginal parameters
#Should IFN signaling be stochastic?
if IFNStoch == :Stochastic
#Keep most parameters the same
θ = fill.(θVals,N,N)
#kcat8 produces IFN, make it nonzero ~20% of the time (can be changed later)
θ[11] .= θVals[11] .* rand(Bernoulli(0.2),N,N)
else
θ = θVals #Just keep the parameters as is (same for each cell)
end
#Now we need to deal with the initial condition
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#Define the initial conditions
u0 = zeros(N,N,species)
if Hetero == :Hetero
noiseDistributions = AddNoise2States(0.5)
for (i,index) in enumerate(nonZeroSpeciesIdx)
u0[:,:,index] = rand(noiseDistributions[i],N,N)
end
else
#Loop through non-zero species and update their concentrations
for (idx,val) in zip(nonZeroSpeciesIdx,nonZeroSpeciesValues)
u0[:,:,idx] .= val
end
end
#Finally need to set the DNA initial condition
if infectionMethod == :ISD
#Define a region on the domain where cells will be infected
circleOrigin = [0,0] #Where is the center of the drop?
circleRadiusSquared = N^2 #How big is the drop?
#Calculate squared distances
sqDist(x,c) = reduce(+, @. (x-c)^2)
#Loop though cells and check if they are infected
for currentCell in cellIndicies
#Are the cells inside the infected region?
if sqDist([currentCell[1],currentCell[2]],circleOrigin) circleRadiusSquared
u0[currentCell,2] = m2c(1e3)
end
end
elseif infectionMethod == :Virus
#Assume a poisson ditribution to randomly choose each cell's level of infection
probDistInfected = Poisson(moi)
u0[:,:,2] = @. m2c(1e3*rand(probDistInfected,N,N))
end
#Need to wrap everything up into the ParContainer struct
mass = [u0[:,:,i] for i in nonZeroSpeciesIdx]
deathParameter = ones(N,N)
DNAReplicate = infectionMethod==:ISD ? 0 : 1
#Keep track of infected cells (save time when infected, Inf means not infected)
cellsInfected = fill(Inf,N,N) #Make constant when not testing
cellsInfected[findall(u0[:,:,2] .> 0.0), 1] .= 0.0
#Keep track of time of death (TOD)
cellsDead = fill(Inf,N,N) #Inf implies alive
#Create an array that keeps track of whether or not a cell has tried to infect neighbors
infectFirstAttempt = trues(N,N)
#Create an instance of the structures
θ = ParContainer(
θ, #Rate constants
mass, #Mass balances
deathParameter, # cell is dead? (1==alive, 0==dead)
DNAReplicate, #can DNA replicate? (1 if virus)
cellsInfected, #Time cell was infected
cellsDead, #Time cell was killed
infectFirstAttempt) #Has cell tried to infect neighbors?)
return ODEProblem(Model!,u0,tspan,θ)
end
110
C.1.6 Function to count the cell states (healthy,infected,dead)
function cellStates(t,θ)
#Number of healthy cells at time t
totaHealthy = sum(θ.cellsInfected .> t)
#Number of dead cells at time t
totalDead = sum(θ.cellsDead .< t)
#Number of infected cells at time t
totalInfected = nCells - totaHealthy - totalDead
return [totaHealthy,totalInfected,totalDead]
end
C.1.7 Display Information about the Parameter Container
function Base.show(io::IO,p::ParContainer)
#Is simulation det/stoch and homo/hetero
attribute1 = isa(p.par[1],Array) ? "Stochastic" : "Deterministic" #True if stochastic
attribute2 = all(p.mass[1][1].==p.mass[1]) ? "Homogeneous" : "Heterogeneous" #True is homo
println("Cell Population: ",attribute1," and ",attribute2)
#What is the Input for DNA?
modelInput = p.DNAReplicate==1 ? "Virus" : "ISD"
println("Model Input: ",modelInput)
#How many cells initially infected?
println("Initially Infected: ",100.0*sum(p.cellsInfected.==0.0)/nCells, "%")
println("Currently Infected: ",100.0*sum(p.cellsInfected.<Inf)/nCells, "%")
#How many cells are initially dead?
println("Dead: ",100.0*((nCells - sum(p.cellsDead.==Inf))/nCells), "%")
#How many cells are not responsive to infection?
if attribute1 == "Stochastic"
println("Cells with kcat7=0: ",100.0*sum(p.par[11].==0.0)/nCells, "%")
end
end
C.2 VirusCallBacks.jl
C.2.1 Callback 1: Healthy → Infected
#Cells are infected after a certain viral load is met (with μ=800 virons, σ=200 virons)
const maxViralLoad = rand(Normal(m2c(800.0),m2c(200.0)),N,N)
function CheckInfect(u,t,integrator)
#Reshape the array into 3D
uReshaped = reshape(u,N,N,species)
#Check the whole virus grid for cells with viral conc. greater than 0.4 nM
return any( @. (uReshaped[:,:,end] > maxViralLoad) & integrator.p.infectFirstAttempt)
end
#These don't need to be constructed every loop
const Index = CartesianIndices(zeros(N,N))
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#Get the first and last index
const Ifirst, Ilast = first(Index), last(Index)
function TryInfect(integrator)
#Probability that an infected cell will spread infection
chanceOfInfection = Bernoulli(0.5)
cellsInfected = integrator.p.cellsInfected
@show integrator.t
#Sundials does not presereve problem shape...
uReshaped = reshape(integrator.u,N,N,species)
#Loop through all of the infectious cells
for I in findall(uReshaped[:,:,end] .> maxViralLoad)
#Loop through all neighbors to see if they get infected
for J in max(Ifirst, I-Ifirst):min(Ilast, I+Ifirst)
#If the cell is healthy and not the current cell try to infect
@inbounds if isinf(cellsInfected[J]) && (I != J) && rand(chanceOfInfection)
#Add Viral DNA to the cell
uReshaped[J,2] = rand(Uniform(0.0,m2c(1e3)))
#Mark that the cell was infected
cellsInfected[J] = integrator.t
end
end
#This cell has used its one attempt to infect neighboring cells
integrator.p.infectFirstAttempt[I] = false
end
integrator.u = uReshaped[:]
end
cbInfect = DiscreteCallback(CheckInfect,TryInfect, save_positions=(false,false))
C.2.2 Callback 2: Infected → Dead
#Cells die some time after infection (with μ=8.0 hours, σ=1.0 hours)
const time2Death = rand(Normal(8.0,1.0),N,N)
function DeathCheck(u,t,integrator)
cellsInfected = integrator.p.cellsInfected
#Loop through and check if a cell should die
cellCounter = 1
while cellCounter < length(cellsInfected)
#If cell infected and cell past time of death
pastTimeOfDeath = (t - cellsInfected[cellCounter]) > time2Death[cellCounter]
isAlive = isinf(integrator.p.cellsDead[cellCounter])
if pastTimeOfDeath & isAlive
return true
end
cellCounter += 1
end
return false
end
function KillCell(integrator)
cellsInfected = integrator.p.cellsInfected
#Find all the cells to kill
pastTimeOfDeath = (integrator.t .- cellsInfected) .> time2Death
isAlive = isinf.(integrator.p.cellsDead)
targets = findall(isAlive .& pastTimeOfDeath)
#println(sum(integrator.p.deathParameter .== 0.0))
#Set their deathParameter to stop all cell function
integrator.p.deathParameter[targets] .= 0.0
#Mark time of death
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integrator.p.cellsDead[targets] .= integrator.t
end
cbDead = DiscreteCallback(DeathCheck,KillCell,save_positions=(false,false))
cb =CallbackSet(cbInfect,cbDead)
C.3 Example Code (Figure 4.3.2)
#Shows what a typical ISD and Viral Infections looks like
using RCall
include("ProblemGenerator.jl")
include("VirusCallBacks.jl")
########################################################################
#Heatmaps of IFN dynamics (Figure 2)
########################################################################
#-----------ISD, Not Stochastic, Homo-----------
probISD_nS_Ho = ModelSetup(:ISD,:notStochastic,:Homo)
solISD_nS_Ho = @time solve(probISD_nS_Ho,CVODE_BDF(linear_solver=:GMRES),saveat=0.1)
ISD_nS_Ho = DataFrame()
ISD_nS_Ho.x = repeat(1:N,N)
ISD_nS_Ho.y = repeat(1:N,inner=N)
ISD_nS_Ho.IFN = vec(solISD_nS_Ho(10.0)[:,:,7])
#-----------Virus, Not Stochastic, Homo-----------
probVirus_nS_Ho = ModelSetup(:Virus,:notStochastic,:Homo)
solVirus_nS_Ho = @time solve(probVirus_nS_Ho,CVODE_BDF(linear_solver=:GMRES),saveat=0.1,callback=cb)
Virus_nS_Ho = DataFrame()
Virus_nS_Ho.x = repeat(1:N,N)
Virus_nS_Ho.y = repeat(1:N,inner=N)
Virus_nS_Ho.IFN = vec(solVirus_nS_Ho(10.0)[:,:,7])
#-----------Virus, Not Stochastic, Homo, Cell States-----------
function CellStateGrid(θ::ParContainer,t::Float64)
grid = zeros(Int64,size(θ.cellsInfected))
grid[θ.cellsInfected .<= t] .= 1
grid[θ.cellsDead .<= t] .= 2
return grid
end
CellStateVirus_nS_Ho_raw = CellStateGrid(probVirus_nS_Ho.p,10.0)
CellStateVirus_nS_Ho = DataFrame()
CellStateVirus_nS_Ho.x = repeat(1:N,N)
CellStateVirus_nS_Ho.y = repeat(1:N,inner=N)
CellStateVirus_nS_Ho.Cell = vec(CellStateVirus_nS_Ho_raw)
#-----------ISD, Stochastic, Hetero-----------
probISD_S_He = ModelSetup(:ISD,:Stochastic,:Hetero)
solISD_S_He = @time solve(probISD_S_He,CVODE_BDF(linear_solver=:GMRES),saveat=0.1)
ISD_S_He = DataFrame()
ISD_S_He.x = repeat(1:N,N)
ISD_S_He.y = repeat(1:N,inner=N)
ISD_S_He.IFN = vec(solISD_S_He(10.0)[:,:,7])
#-----------Virus, Stochastic, Hetero-----------
probVirus_S_He = ModelSetup(:Virus,:Stochastic,:Hetero)
solVirus_S_He = @time solve(probVirus_S_He,CVODE_BDF(linear_solver=:GMRES),saveat=0.1,callback=cb)
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Virus_S_He = DataFrame()
Virus_S_He.x = repeat(1:N,N)
Virus_S_He.y = repeat(1:N,inner=N)
Virus_S_He.IFN = vec(solVirus_S_He(10.0)[:,:,7])
#-----------Virus, Not Stochastic, Homo, Cell States-----------
CellStateVirus_S_He_raw = CellStateGrid(probVirus_S_He.p,10.0)
CellStateVirus_S_He = DataFrame()
CellStateVirus_S_He.x = repeat(1:N,N)
CellStateVirus_S_He.y = repeat(1:N,inner=N)
CellStateVirus_S_He.Cell = vec(CellStateVirus_S_He_raw)
#-----------R Plot-----------
@rput ISD_nS_Ho
@rput Virus_nS_Ho
@rput CellStateVirus_nS_Ho
@rput ISD_S_He
@rput Virus_S_He
@rput CellStateVirus_S_He
R"""
library(ggplot2)
library(ggpubr)
#To draw an arc on the heatmap to show initial condition
arc <- data.frame(
x0 = seq(0, 200, length.out = 1000),
y0 = sqrt(200^2 - (seq(0, 200, length.out = 1000)^2))
)
#Color Range
clim = c(min(ISD_S_He$IFN), max(ISD_nS_Ho$IFN))
commonFigureOptions <- list(scale_fill_distiller(palette = "Spectral",
guide = guide_colorbar(frame.colour = "black", ticks.colour = "black"),
limits = clim),
scale_x_continuous(expand=c(0,0)),
scale_y_continuous(expand=c(0,0)),
theme_bw(base_size = 12),
ylab("Cell"),
xlab("Cell"),
labs(fill="IFN (nM)"),
theme(plot.title = element_text(hjust = 0.5),aspect.ratio = 1))
p1 <- ggplot() +
geom_raster(ISD_nS_Ho, mapping =aes(x, y, fill=IFN)) +
geom_line(data=arc, aes(x=x0, y=y0),size=0.2,linetype="dashed") +
labs(fill="IFN (nM)") +
ggtitle("ISD \n Deterministic \n Homogeneous") +
commonFigureOptions
p2 <- ggplot(Virus_nS_Ho, aes(x, y, fill=IFN)) +
geom_raster(aes(fill=IFN)) +
ggtitle("Virus \n Deterministic \n Homogeneous") +
commonFigureOptions
p3 <- ggplot(CellStateVirus_nS_Ho, aes(x, y, fill=factor(Cell))) +
geom_raster(aes(fill=factor(Cell))) +
scale_fill_manual(values=c("#377EB8","#4DAF4A","#E41A1C"),labels = c("Healthy", "Infected","Dead")) +
scale_x_continuous(expand=c(0,0)) +
scale_y_continuous(expand=c(0,0)) +
theme_bw() +
labs(title ="Viral \n Infection \n Cell States", x="Cell", y="Cell", fill = "Cell State") +
theme(plot.title = element_text(hjust = 0.5),aspect.ratio = 1)
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p4 <- ggplot() +
geom_raster(ISD_S_He, mapping =aes(x, y, fill=IFN)) +
geom_line(data=arc, aes(x=x0, y=y0),size=0.2,linetype="dashed") +
ggtitle("ISD \n Stochastic \n Heterogeneous") +
commonFigureOptions
p5 <- ggplot(Virus_S_He, aes(x, y, fill=IFN)) +
geom_raster(aes(fill=IFN)) +
ggtitle("Virus \n Stochastic \n Heterogeneous") +
commonFigureOptions
p6 <- ggplot(CellStateVirus_S_He, aes(x, y, fill=factor(Cell))) +
geom_raster(aes(fill=factor(Cell))) +
scale_fill_manual(values=c("#377EB8","#4DAF4A","#E41A1C"),labels = c("Healthy", "Infected","Dead")) +
scale_x_continuous(expand=c(0,0)) +
scale_y_continuous(expand=c(0,0)) +
theme_bw() +
labs(title ="Viral \n Infection \n Cell States",x="Cell", y="Cell", fill = "Cell State") +
theme(plot.title = element_text(hjust = 0.5),aspect.ratio = 1)
figure1 <- ggarrange(p1, p2, p3, p4, p5, p6,
labels = "AUTO",
align = "h",
ncol = 3, nrow = 2)
ggsave("./Figures/Figure2New.pdf",width=12,height=8,units="in")
"""
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